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ABSTRACT 
 
Michael Joseph Hackett: Paclitaxel-2'-O-pentadecylhemiglutarate: A Prodrug Strategy for 
Albumin Based Drug Delivery (Under the direction of Moo J. Cho, Ph.D.) 
  
Delivery of antineoplastic agents to solid tumors remains a great challenge in 
formulation development.  Preclinical successes often do not translate into clinical therapies 
due to the intrinsic imperfections of current models.  The presented formulation begins with 
clinical observations indicating the ubiquitous protein, serum albumin, naturally accumulates 
selectively in spontaneously developed tumors.  Albumin then provides a natural shuttle for 
therapeutic agents to solid tumors.  To test this, a fatty diacid, 3-pentadecylglutaric acid 
(PDG), was synthesized.  This fatty acid has the capacity to bind albumin tightly while 
concomitantly binding a therapeutic moiety, in this case paclitaxel.  The paclitaxel-2'-O-
pentadecylhemiglutarate conjugate binds albumin tightly but the extreme hydrophobicity led 
to poor loading efficiency and the formation of 120 nm albumin aggregates; a similar 
phenomenon observed in the clinically approved ABRAXANE.  This aggregation was found 
to be the result of a specific interaction between paclitaxel and albumin.   
Dissociation of the conjugate from albumin is exceedingly slow with less than 3% 
released over 48 h under sink conditions.  When administered to tumor bearing mice, the 
formulation behaved similarly to covalently attached albumin conjugates.  Rapid and uniform 
organ distribution was observed followed by a slow re-emergence of complex into the 
vasculature giving rise to a half-life of 23 h. This is comparable to the half-life of the protein 
itself in mice.  Tumor accumulation was moderate (~1%) and biochemical stability analysis 
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of the conjugate suggests little conversion (<6% over 72 h) to free drug would occur.  
Despite decreased cytotoxicity, lower doses of the conjugate demonstrated comparable 
efficacy to TAXOL without the need for surfactants. 
Modification of paclitaxel was accomplished in a single step using PDG anhydride 
presenting a cost-effective method for improving the pharmacokinetics of a drug.  
Conceptually, this study lays the foundation for using the PDG technology for modifying 
other therapeutic agents. The success of the formulation is highly dependent on the 
selected therapeutic modality which can be broadly limited to any therapeutic agent bearing 
a nucleophilic moiety.  It is expected a more hydrophilic drug that does not exhibit albumin 
binding may lead to increased efficacy in addition to improved pharmacokinetics.    
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PREFACE 
 
I was trained as a synthetic chemist by Phil Garner, Ph.D. at Case Western as an 
undergraduate.  While I enjoyed it, I was unfulfilled and wanted a way to translate the 
compounds I made into medically useful products.  I thus applied to the Medicinal Chemistry 
program at the UNC School of Pharmacy, or so I thought.  During website reconstruction, 
the Med Chem website was down and assuming the four listed programs were all just 
ramifications of one program, I used the information for the only functional website; 
Molecular Pharmaceutics.  I received a call from Dr. Cho informing me of my mistake along 
with an elevator pitch on behalf of the MoPh program.  I had never heard of drug delivery 
but the idea of designing drugs to be delivered specifically within the body sounded as 
amazing as it did impossible.  Intrigued, I recalled the best advice, courtesy of Dr. Garner, I 
received while looking for grad schools; “follow the science.”  So I did and joined the MoPh 
program in the summer of 2006 to the elation of the Med Chem department I am sure.   
After a rotation with Dr. Huang, I recall talking to Cho about joining his lab to work on 
PRINT particles.  On my first day I entered the lab and the smell of aldrithiol and 
dichloromethane washed over me; I knew I was home.  Well, first I replaced the 
dichloromethane smell with ether.  Then I knew I was home.  Cho and I worked on a few 
preliminary projects together while I finished classes, but the projects were unsuccessful.  
Cho then discussed a project of using a fatty acid for binding albumin.  He mentioned it in 
passing as an interesting idea but having had several students take on the idea and fail in 
the past, he had all but given up hope.  I loved the idea and immediately set to work making 
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the same mistakes as everyone in the past.  Then, after some 30 trips back to the drawing 
board, I scribbled out a new molecule to make my life easier.  Like Archimedes standing in 
the tub only to notice the water level rise, or the apple falling on Newton’s head; I too had a 
Eureka moment.  I showed the molecule to Cho who immediately shared my enthusiasm, 
and within a few hours I returned with a synthetic scheme to make the 3-cetylglutaric 
anhydride.   
Several months later, having survived the LAH and KCN involved in the synthesis, I 
was purifying over a gram of the molecule in AcCl by filtration.  Some water was aspirated 
into the vacuum flask which immediately reacted with the AcCl releasing a great deal of heat 
which exploded the suspension out the top of the filter barely missing my and Patrick 
Guley’s faces.  Rather than restart the synthesis, I decided to keep my face and design a 
new one.  Again, within a day I had designed a brand new synthesis which shortened the 
number of steps and the toxicity of the involved reagents and . . . it failed . . . consistently.  
Eventually it was tweaked into the synthesis presented in Chapter III which is shorter, easier 
and less dangerous than the initial synthesis.  Recently we’ve even thought of shortening it 
further via Michael addition of a Grignard but that’s another story.  The result was the 3-
cetylglutaric anhydride truncated by one methylene; 3-pentadecylglutaric anhydride now 
affectionately named PDG. 
Cho’s idea of using a fatty acid to bind albumin was coming to fruition and our zeal 
prompted us to take off at breakneck speed; only to realize we had no idea where we were 
going.  Eventually we regained our composure and focus.   We had not been averse to 
challenges up to this point nor were we strangers to struggle.  So we decided to shoot for 
the moon and undertook paclitaxel as our first endeavor.  Edison said it best. 
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  “If I find 10,000 ways something won't work, I haven't failed. 
 I am not discouraged, because every wrong attempt discarded 
 is another step forward.” 
      -Thomas Alva Edison   
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FORMULATIONS OF PACLITAXEL: REVIEW 
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1. Introduction 
Paclitaxel (PTX) is a water-insoluble taxane primarily indicated for the treatment of 
breast, non-small cell lung and ovarian cancers.  As a small molecule, PTX can move swiftly 
by diffusion dictated only by a concentration gradient.  Peripheral delivery of PTX can then 
be effective locally as well as distributing throughout the tumor core.  PTX molecules can 
easily partition into tumor cell membranes followed by slower release into the cytosol for 
microtubule bundling. For PTX to be effective in eradicating a solid tumor, it must accrue a 
minimum required concentration sustained for a desired period of time.  Accumulation of a 
large fraction of the total dose at the target site warrants a safer, more effective treatment; a 
corollary being shortened and/or fewer doses.  Most of the recent developmental efforts 
have incorporated mechanisms to achieve the pharmaceutical requirements presented 
above. Chemical efforts for identifying other taxane analogs have met the same fate of rapid 
clearance (1, 2). Likewise, approaches with PTX derivatives including chemical delivery 
systems (i.e., prodrugs) have also been far from achieving delivery targeted to solid tumor 
(3, 4).    This dilemma in developing a parenteral formulation for lipophilic antineoplastic 
agents for targeted delivery to a solid tumor is not a unique problem with PTX.  This general 
problem is indeed one of the most challenging issues contemporary research scientists are 
facing.   
2. The Problems Associated with TAXOL 
Like any other water-insoluble drug molecules, PTX will not be present in the 
circulation as a molecular dispersion (i.e., true solution).  At a therapeutically meaningful 
concentration (~ 1 µM), over 95% of PTX exists as bound to serum albumin and 
orosomucoid and a smaller amount bound to LDL/HDL (5, 6). Since the concentration of 
albumin (~40-50 mg/ml) is much greater than the other proteins, the majority of PTX in the 
circulation should be bound to albumin.  Its 1:1 specific binding to albumin is with an 
3 
 
association constant close to 106 M-1 while multiple non-specific bindings are estimated by 
molecular docking to be approximately 105 M-1 (7). Observed values tend to suggest weaker 
binding (8).  The compound has a lower affinity for erythrocytes and platelets but a very high 
affinity for the major surfactant in Cremophor EL (CrEL), polyethyleneglycol 
glyceroltriricinoleate.  In the presence of CrEL, very little protein binding occurs and an 
entirely different pharmacokinetic profile emerges (9).  Due to the complex nature of the 
various interactions, the pharmacokinetics observed subsequent to IV injection of CrEL-
based PTX formulation (i.e., TAXOL) can lie anywhere between the kinetics of albumin 
bound PTX and CrEL encapsulated PTX. 
The result is a rapid elimination of PTX from the circulation; 90% of PTX disappears 
within 3.5 hrs after 3-hr infusion in cancer patients (10). This is patently not due to metabolic 
degradation since the sum of major metabolites at a given time is less than 1% of the total 
(11). If one considers the long plasma half-life of albumin, ~ 19 days in humans (12), the 
above finding agrees with the facile transfer of PTX from its albumin complex to CrEL.  PTX 
tends to accumulate in the liver where metabolism and biliary excretion occur (13).  The 
rapid clearance has detrimental implications in delivery of PTX to the solid tumor. In this 
context, a more suitable vehicle must be employed for effective tumor delivery to see 
substantial improvements over TAXOL. 
TAXOL is a 1.2 mg/mL emulsion in 10% EtOH, 10% Cremophor EL and 80% normal 
saline which is commonly infused over 3 hours every 2-3 weeks.  The large quantity of CrEL 
is not well tolerated with most patients causing grade IV neutropenia and grade III 
hypersensitivity thus requiring a prophylactic regimen of dexamethasone (14).  Being so 
abundant, the surfactant is believed to saturate the liver thus retarding the extravasation and 
consequential metabolism and elimination of PTX (9).  This gives rise to non-linear or dose-
dependent pharmacokinetics showing disproportionately slower elimination of the drug at 
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higher doses.  Coupled with multiple cytochrome P450 dependent metabolism, this leads to 
significant inter-individual pharmacokinetics and difficult dosing of TAXOL (15).  Constrained 
within the linear kinetic range, TAXOL is cleared rapidly from the body with a terminal half-
life of 4 h when administered as a 6 h infusion (16).  Outside the linear kinetic range at 
higher dosing or shorter infusions, for example 3 h, the half-life increases to 7-8 h (10).  The 
accumulation of TAXOL in solid tumors is minimal leading to non-specific tissue uptake and 
toxicity.  Despite this undesirable phenomenon, TAXOL is highly prescribed and moderately 
effective speaking volumes to the potency of the drug.  A targeted formulation containing 
PTX should prove much more effective and tolerable for patients.   
3. Desired Features of PTX Formulations  
Drug delivery is an emerging field defined by a desire to formulate drugs for 
increased accumulation in a specific target tissue while minimizing non-specific 
accumulation and accompanying toxicity.  This can be accomplished in several ways such 
as a benign prodrug only activated under specific tissue conditions, targeting to a specific 
feature of a tissue by way of a targeting ligand, affiliation with a carrier or any combination 
therein.  For development of a new formulation, there are many attributes to consider (17-
19).  This review will focus on the desirable characteristics as they pertain to PTX. 
Solubility.  Paclitaxel is poorly soluble at 10 ug/mL in water at room temperature (20).  
The ideal formulation should be able to solubilize PTX ad infinitum such that it can be 
sterilized in a conventional manner and administered parenterally without further 
manipulations such as reconstitution or mixing with other solutions. The drug concentration 
in the formulation should be high so bolus injection is possible.   Given the physicochemical 
properties of PTX, these may be impossible requirements to satisfy. 
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In Vivo Stability.  When administered intravenously as TAXOL, PTX binds albumin, 
orosomucoid, endothelial cells, erythrocytes, platelets, while presumably residing inside the 
CrEL micelles for a significant period of time.  Ideally a delivery vehicle should preclude non-
specific association of the drug such as this while in the serum.  The formulation should be 
biochemically stable and resist hepatic, renal and reticuloendothelial clearance. Then the 
drug will be available for tumor-targeted delivery.  All organs are characterized by having 
leaky vasculature depending on the structure of endothelium.  A normal continuous 
endothelium has pores sizes between 1.8-2.0 nm which prevents extravasation of most 
macromolecules (21).  As an example, albumin of molecular weight 66.5 kDa has an 
assumed diameter of approximately 4 nm with the longest dimension extending 9.5 nm (22).  
In rapidly growing tumors, the vasculature can be quite leaky with large gaps in the vicinal 
endothelium.  Observed pores in the tumor endothelia can be much larger ranging from 200 
- 2000 nm (23).  Compare this to the kidney which is defined by having fenestrated 
endothelia of approximately 12-30 nm (21).  The endothelium here tends to be anionic 
making it resistant to most serum proteins carrying net negative charges while facilitating 
extravasation of cationic carriers.  The liver and spleen are defined by having sinusoidal or 
discontinuous endothelia with pores up to 150 nm (21).  These endothelia are also anionic 
thus having a higher extraction of cationic carriers.   
The liver and spleen are lined with highly phagocytic cells attributed to the filtration of 
particles from the vasculature.  Collectively they are called the reticuloendothelial system 
(RES).  These cells can be avoided in several ways including steric hindrance via the 
addition of polyetheyleneglycol (PEG), minimizing opsonization and the inability to 
extravasate effectively through the sinusoidal endothelia (24).    Considering the large 
difference in vascular pores between the tumor and the liver, a large carrier can facilitate 
RES aversion but still effectively extravasate into the tumor.  Smaller particles, typically 20 
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nm or less, appear able to avoid RES uptake as well (25).  Lastly, if the carrier is or appears 
natural, it may have an inherent resistance.  Macrophages, for instance, have been shown 
to express FcRn, the albumin/IgG protection receptor (26).  The measure of a successful 
formulation will be a protracted serum half-life.   This is desirable as the crowded tumor can 
only slowly filter the blood thus a prolonged retention in the circulation will promote a 
sustainable infusion of drug into the tumor. 
Targeting.  Targeting can occur passively or actively.  Passive targeting to tumors is 
typically attributed to the leaky vasculature associated with the vicinal endothelium (27).  
Rapidly expanding tumors compromise lymphatic drainage while concomitantly inundating 
the endothelium with a deluge of growth factors.  Macromolecules in the circulation are then 
filtered into the tumor, similar to the spleen and liver.  Once in the tumor periphery, active 
targeting can be accomplished by presentation of a tumor-specific targeting ligand.  This 
ligand can be directly attached to the carrier, often with a linker, minimizing steric hindrance 
for specific receptors overexpressed on tumor cells.  This provides a greater chance of 
tumor cell encounter and subsequent endocytosis.  Examples include nutrients such as 
tetrahydrofolate (28), hormones such as tamoxifen (29) or peptides such as the tripeptide 
Arg-Gly-Asp (RGD) which targets integrin proteins on the endothelium (30).  
Release.  With the highly convective force of blood pushing macromolecules out of 
the vasculature into the tumor periphery but with no mode of drainage, convective forces 
within the tumor weaken and diffusion predominates (31).  Small molecules then are 
unrestricted as they are driven by diffusion, but macromolecular carrier or therapeutic 
motility will be greatly impeded.  Ideally, PTX should be released at this time in the tumor 
periphery.  This can occur by manipulating specific elements of the tissue such as acidity, 
enzyme expression or internalization into cells. The tumor microenvironment is moderately 
acidic compared with normal tissue with a pH around 6-7 (32).  A very highly acid sensitive 
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compound such as carboxylated dimethyl maleic acid could facilitate release (33).  Enzyme 
overexpression tends to be tumor dependent.  Some general examples of targeted enzymes 
include the cathepsins (34) and matrix metalloproteases (MMPs) (35), both of which are 
involved in cleavage of the extracellular matrix to allow rapid growth (36).   
If the carrier is endocytosed by tumor cells, it will be processed into a mature 
endosome and subsequent lysosome.  The mature endosome provides a checkpoint for 
release of chemically attached PTX from the carrier as well as endosomal transfer of the 
carrier to the cytosol.  One method for endosomal release requires a weak base. During 
endosomal maturation, V-class proton pumps decrease the pH inside endosomes to 
approximately 5.  This proton flux can be buffered by a weak base triggering more protons 
to be pumped.  As protons enter the endosome, chloride counter-ions follow.  This creates 
an osmotic gradient prompting the diffusion of water into the endosome with subsequent 
swelling and potential rupture or leakage from endosome to cytosol.  This mechanism is 
referred to as the proton sponge hypothesis (37).  Other methods include membrane 
disruption (38) or the use of highly cationic cell penetrating peptides such as the 
transactivator of transcription (TAT) peptide from human immunodeficiency virus (39).  The 
result should be the complete release of PTX from the carrier and the released vehicle 
should be non-toxic and non-immunogenic.  
Development.  From a manufacturing perspective, a vehicle should be simple.  It 
should be highly scalable, economical and easy to manufacture.  From a practitioner’s 
perspective, the commercial formulation should be stable, easy to formulate for 
administration and be administered quickly, infrequently and innocuously. 
Many alternative formulations to TAXOL have been proposed.  These run the gamut 
from clinically approved through preclinical proof of concept.  There is no known magic 
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bullet formulation for PTX and these ideal characteristics are meant only as a basis of 
comparison.  The great number and variation in the methods of PTX delivery are 
nevertheless encouraging. 
4. Natural Drug Carriers  
There are several options available for natural carriers but the most commonly used 
is also the most abundant, serum albumin. Albumin is maintained at ~40-50 mg/mL 
concentrations in the vasculature and 25 mg/mL in the interstice; twice as great as the 
penultimately abundant, IgG (40).  Both albumin and IgG are naturally protected from 
degradation throughout the body by the Brambell receptor, FcRn (12).  While expressed on 
all endothelia, FcRn has now been discovered in the kidney (41), hepatocytes (42) and on 
monocytes (26).  This protection is manifest in 19 and 21 day half-lives for albumin and IgG 
respectively, in humans. This perfectly satisfies the pharmacokinetic requirements for 
formulation development (12).  In addition to natural protection, albumin both passively and 
actively deposits in solid tumors where it is rapidly degraded; putatively because the most 
abundant protein provides the most abundant sustenance (43).  Passive accumulation of 
albumin is believed to occur due to the leaky vasculature of the tumor endothelium (27).  
Active accumulation is believed to occur via an overexpression of albondin (gp60) and 
secreted protein acidic and rich in cysteines, SPARC, at the tumor endothelium (44).  These 
proteins are responsible for albumin flux into the interstice; gp60 transcellularly and SPARC 
paracellularly.  Despite this accumulation, albumin is still degraded extensively throughout 
the body; 15% in the liver (45), 10% in the kidneys (46) and 40-60% in the muscle and skin 
(47, 48). Other potential natural carriers include IgG, LDL/HDL and transferrin which all 
demonstrate similar passive tumor accumulation as albumin (49, 50).  The half-lives of LDL 
and transferrin can drop to 1/3 of their intrinsic half-life due to catabolism by a growing 
tumor.  Consequently, these particles are naturally programmed carriers for tumoral delivery 
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although little has been done with these particles for PTX delivery.  Synthetic LDL has been 
formulated and administered (51, 52) while transferrin has been used primarily as a 
targeting ligand (53, 54). 
The only clinically approved alternative to TAXOL is Abi-007 (ABRAXANE).  
ABRAXANE is formulated by suspending PTX with albumin followed by nebulization under 
high pressure.  This consequently entraps the hydrophobic PTX molecules inside the 
albumin core resulting in 130 nm particles.  This greatly narrows the technology to apply 
only to hydrophobic drugs with moderately high affinity for albumin.  The particles are 
believed to break down in serum but the albumin may or may not retain the native form.  If 
the albumin is unable to refold properly, it could reduce or relinquish its affinity for all major 
receptors.  This does not appear to be the case for gp60 or SPARC (44), but at the time of 
this writing there has been no mention associating ABRAXANE with FcRn.  ABRAXANE is 
much better tolerated than TAXOL and docetaxel allowing greater doses of PTX and shorter 
30 minute infusions on the same schedule as TAXOL; every 3 weeks (44, 55, 56).  A dose 
of ABRAXANE contains 100 mg of PTX for every 900 mg albumin or about 8.5 eq of PTX 
per albumin for a 10% loading capacity.  The complexity of formulation requires recombinant 
albumin instead of native albumin extant in the patient. 
Another technology utilizing albumin involves a PTX prodrug attached to a tumor- 
specific cleavable peptide and a free maleimide (Fig. I-1) (57).  Albumin is known to have 35 
cysteines with 17 locked in disulfides leaving only Cys34 with a free thiol.  This thiol is known 
to react quickly via Michael addition across maleimides.  Unlike ABRAXANE, this approach 
does use the native albumin of the patient with efficient binding complete within 30 minutes.  
It then has a tumor specific release mechanism for prostate cancer due to the 
overexpression of prostate-specific antigen (PSA).  This allows flexibility to generate tumor- 
specific release mechanisms for various malignancies as well as a more generalized  
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Figure I-1. Synthesis and theoretical in vivo decomposition of the sequentially labile Michael 
adduct of PTX. When albumin begins to accumulate in a solid tumor, specific cleavage by 
the often prostate-specific antigen (PSA) facilitates spontaneous decomposition of the p-
aminobenzyloxycarbonyl (PABC) carbonate at the 2’-OH of PTX releasing the free drug.  
The free drug is then able to diffuse throughout the tumor tissue.  Figure reproduced with 
permission from Eur J Cancer (57). 
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approach for a commonly overexpressed enzyme such as cathepsins or matrix 
metalloproteases (MMPs).  Scalability can be expensive requiring the synthesis of a 
hexapeptide-maleimide conjugate and subsequent condensation with a Leu-p-
aminobenzyloxycarbonyl-PTX conjugate.  As demonstrated, this only allows a 1:1 
albumin:PTX construct which constitutes about 1% loading capacity.  Adding more PTX 
molecules is synthetically feasible but they will be conjugated further from the carrier which 
could subsequently destabilize the construct.  This technology is not cargo specific, and has 
been demonstrated with a variety of drugs including doxorubicin (ε-
maleimidocaproyl)hydrazone (Doxo-EMCH) which is in clinical trials (58).  With minor 
chemical modifications this technology could potentially allow the simultaneous injection of 
multiple classes of drugs for combination therapy (59).  
When administered intravenously, maleimide-based albumin conjugates dilute about 
90% during the distribution phase as albumin permeates the body extensively.  After 
equilibration, the conjugates will slowly eliminate with half-lives approaching that of the 
native protein.  This is demonstrated in Fig. I-2 where a maleimide derivative of an anti-HIV 
peptide is chemically conjugated to albumin in vivo (60).  The observed half-lives of 25.8 h 
for rats and 102.4 h for rhesus monkeys correlate well with the half-lives of intact albumin; 1 
and 5 days respectively.  Extrapolation of these data suggests the half-life of albumin 
conjugates in humans could approach 19 days.   
Albumin is intrinsically a useful carrier for antineoplastics.  It also has many useful 
features for drug loading.  Albumin is a fatty acid carrier having 6-7 binding sites in the 
nanomolar dissociation range (61).  This could be exploited by the use of acylated prodrugs.  
This technique would not require recombinant albumin, provided the prodrug is soluble as 
micelles, and would not be constrained to any specific drug molecule.  An example of this is 
the long-circulating insulin detemir (LEVEMIR) (62).  This technique allows a moderate  
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Figure I-2. Serum pharmacokinetics of an anti-HIV peptide conjugated to Cys34 of albumin.  
Both panels show a ten-fold decrease in concentration prior to the protracted half-life.  This 
is not clearance from the system but distribution throughout the body.  At equilibrium, the re-
emergence of extravascular conjugate into the circulation is what gives rise to the long 
terminal half-life.  Results in rats (A) and rhesus monkeys (B) show half-lives of 1 and 4.3 
days which corresponds well with the half-lives of native albumin in the respective species.  
Figure reproduced with permission from Antimicrob Agents Chemother (60). 
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drug:carrier ratio, although not as high as ABRAXANE.  While albumin does accumulate in 
tumors, it also extensively permeates the tissues, particularly muscle, giving the prodrugs 
ample time for dissociation (63).  Binding of fatty acids does cause a natural transition in the 
structure of albumin (64) which may or may not affect the affinity for intrinsic receptors.  
Albumin has many nucleophlic lysines and electrophilic glutaric/aspartic anhydrides which 
can be used for direct conjugation of a large quantity of drugs.  This is not cargo specific and 
could allow a large proportion of drug loading but would be difficult to accomplish in vivo 
thus requiring recombinant albumin.  Additionally, it has been shown the more lysine 
residues that are modified, the affinity for the gp60 receptor drops while the affinity for 
scavenger receptors such as gp18 and gp30 increase (65, 66).  This could greatly reduce 
the circulation life of the complex.   
5. Synthetic Macromolecular Drug Carriers   
Synthetic carriers offer another opportunity for drug delivery.  Because they are 
entirely synthetic, they can be constructed to specific dimensions and functionality providing 
meticulous control over the final product.  This can allow the generation of very high 
capacity carriers with mechanisms for triggered drug release.  Once built to the desired size, 
the carrier can be derivatized with cargo, targeting moieties, steric protection, release 
mechanisms; all the important components necessary for a successful delivery vehicle.  This 
is necessary as these carriers, despite often being made of natural products, are biologically 
foreign and treated as such.  Overcoming this resistance can lead to the addition of many 
amenities which can be synthetically taxing and expensive. 
An example of a polymer made of natural components is the amino acid based 
scaffold of poly-(L)-glutamic acid (PLG).  PLG-PTX completed phase III clinical trials but was 
not sufficient to file a new drug application (67, 68).  PLG-PTX begins with a 36-kDa polymer 
of repeating glutamic acid residues which are coupled with the 2’-OH on PTX attaining 20% 
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loading capacity (69).  This prodrug should be quite labile due to large quantities of 
esterases and peptidases with non-specific hydrolytic activity.  Being amino acid based, 
degradation of the particles occurs readily, however, release of PTX from the polymer is 
slow (70).  PTX is released as a monoglutamyl ester at the 2’-OH.  Comparable doses of 
PTX versus PLG-PTX show PLG-PTX is less potent.  This is most likely due to the inability 
of the glutamyl-PTX monomer to bind tubulin as is seen with succinic acid derivatives at the 
2’-OH of PTX (71-73).  PLG-PTX shows mostly accumulation in the spleen and liver, 
followed closely by the kidneys and lungs.  The accumulation in the tumor is about a quarter 
of the liver and spleen accumulation per gram of tissue.  All these organs have persistent 
concentrations of drug, even after 6 days (74).  Since PLG-PTX is completely chemistry 
based, it has the potential for further modification with a release mechanism similar to the 
aforementioned p-aminobenzyloxycarbonyl (PABC). This could facilitate PTX release 
without greatly affecting the synthetic load, the solubility or the drug loading.  The addition of 
another equivalent of glutamic acid residues prior to PTX allows an increase in the loading 
capacity of the polymer and resulted in the spontaneous formation of ~20 nm particles which 
could greatly alter the pharmacokinetics of the formulation (75).    
Similar to PLG, other benign polymers can be formulated such as polylactic-co-
glycolic acid (PLGA) polymers.  These lipophilic polymers are water insoluble and thus 
dissolved in a solvent such as chloroform.  As opposed to chemical conjugation, these 
polymers form coacervates around the hydrophobic molecules.  Dissolution of PTX and 
PLGA as well as polyethyleneglycol-biotin modified polylactic acid are added to a 2.5% o/w 
emulsion (76).  The 40 kDa PLGA polymers can adsorb at the interface with PTX in the 
core.  Replacing the oil phase with water stabilizes the 220 nm coacervate due to van der 
Waals interactions with PTX.  This method allowed up to 18% drug loading of a biotin 
targeted formulation.  Pharmacokinetic (PK) analysis was not performed but the formulation 
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showed only 20-30% drug leakage over 3 days in PBS at 37°C.  This led to only a very 
moderate increase in efficacy (76).  Other PLGA formulations have been derivatized with 
various targeting ligands such as the RGD peptide (77), wheat germ agglutinin (78) and 
transferrin (79).  The half-life of the transferrin-modified PLGA particles is about 5.5 h and 
biodistribution shows primarily uptake in the liver, spleen and kidneys indicative of filtration 
and reticuloendothelial system (RES) sequestration (79).  This is surprising although not 
uncommon as the particles of about 200 nm diameter should be too large for the various 
fenestrations aside from the tumor.  This distribution is most likely a result of a high degree 
of shear flexibility promoting extravasation.      
Another class of synthetic polymers is dendrimers which have been used extensively 
and are some of the more highly functionalized of the synthetic carriers.  Traditional 
polyamidoamine (PAMAM) dendrimers are symmetrical polymers built by alternating 
ethylenediamine and methyl acrylate moieties (80).  Initially ethylenediamine is reacted with 
4 equivalents of methyl acrylate via Michael addition resulting in 4 methyl esters.  This is 
called generation 0.5 (G0.5). Next, all the esters are condensed with a large excess of 
ethylenediamine.  This keeps the net number of functional groups constant but converts the 
surface to cationic amines and the generation is incremented by a half-step; G1.0.  Cationic 
dendrimers are known to be toxic so the final condensation can be done with ethanolamine 
allowing which coats the surface with primary alcohols.  This removes the charge from the 
surface of the dendrimer whil still providing a nucleophilic moiety for functionalization (81).  
Alternatively, the amines can be capped, most commonly with acetyl groups.   
One such formulation began with a G5 dendrimer with 82 out of 110 primary amines 
acetylated. To the remaining amines were grafted 2’-O-paclitaxelhemisuccinate, 
fluoresceinisothiocyanate (FITC) and tetrahydrofolate as a drug, tracer and targeting ligand 
respectively (Fig. I-3)  (80).  The final product contained an average 5 FITC fluorescent  
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Figure I-3. Structure of G5 dendrimer derivatized with paclitaxel (PTX), folic acid (FA) and 
fluoresceinisothiocyanate (FITC).  This construct is designed to target tumor cells which 
commonly overexpress the folate receptor. The PTX is used for cytotoxicity and FITC as a 
fluorescent tracer.  At 20 nm, diffusion of the dendrimer in the tumor environment will be 
minimal, so uptake will most likely occur peripherally.  Figure reproduced with permission 
from Biomacromolecules (80). 
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tracers, 4.8 folates and 3 PTX succinate molecules per dendrimer.  The loading capacity in 
this formulation is low (~6%) but can be improved via the addition of triazine moieties 
allowing triple the cargo loading without a large increase in size (82).  These dendrimers 
allowed 18-30% PTX loading by mass with ~18% by weight dendrimer and the rest 
polyethyleneglycol (PEG).  Each dendrimer is approximately 26 kDa which is roughly 1/3 of 
an albumin molecule so the loading capacity is comparable to ABRAXANE.  Being 
comparable to albumin in final molecular weight, it will utilize mostly convection for 
movement, redering diffusion within the tumor a slow processs.  Due to their size, 
dendrimers should be essentially invisible to phagocytic systems.  The dendrimers will 
however be subject to extravasation through the sinusoids of the liver and the smaller 
fenestrations in the kidneys, particularly if the dendrimer is cationic.  
While the folate receptor is ubiquitous, it is highly overexpressed in several tumor cell 
lines which would promote receptor mediated endocytosis in the tumor microenvironment 
(83).  The large number of unused amines and capped amines allows the potential for 
conjugating more drug or more targeting ligand.  This could improve toxicity and avidity and 
could be titrated to find an optimal ratio.  Grafted on the dendrimer surface, the folate may 
not be readily accessible to the folate receptors, however this could be remedied by 
conjugating PEG moieties with folate on the distal end.  Due to diffusion constraints, the 
dendrimers will most likely only encounter folate receptors on peripheral tumor cells.  Once 
internalized the dendrimer has a built-in endosomal escape mechanism with the internal 
tertiary amines providing a weak base to act as a proton sponge.     
Drug release does not have to be induced by peptidases or esterases alone. Alternative 
release mechanisms include the PABC self-immolative release mechanism (84) mentioned 
earlier as well as disulfides (85) which can release in the cytosol and possibly the 
endosome.  Thermally-sensitive dendrimers have also been developed which can promote 
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drug release due to specific heating of the tumor environment (86).  This has been 
accomplished in the past for thermally-sensitive liposomes (87) by use of near-infrared 
lasers (88). Recently it has been proposed dendrimers be rendered entirely self-immolative 
(89).  This technique, if the trigger can be highly tumor specific, would allow complete and 
instantaneous release of the drug at the active site along with the benign building blocks of 
the dendrimer.  An acid-sensitive cap or enzyme-specific cap could be a very useful 
triggering mechanism, particularly for endosomal release.  If a single dendrimer coated with 
a targeting ligand and PTX were endoctyosed, it would have the osmotic pressure of a 
single molecule.  If upon acidification, the entire dendrimer immolated into 1000 non or 
monoionized membrane impermeable fragments, the osmotic pressure should theoretically 
increase 1000 fold.  This alone may potentially be a useful tool for endosomal escape for 
larger membrane impermeable therapies. 
6. Lipid-Based Formulations 
One technology undergoing phase III clinical trials is a stabilized nanoemulsion 
containing PTX.  The α-tocopherolpolyethyleneglycolsuccinate (TPGS), nanodroplets of 
about 40-80 nm contain a derivative of vitamin E, and 10 mg/mL PTX.  This is higher than 
TAXOL (1.2 mg/mL) but the loading capacity is comparatively low at about 8% (90).  The 
concentrations attained with this formulation are much greater thus expediting infusion times 
to 15 minutes.  The simplicity of the formulation and familiarity of administration are 
beneficial but despite the better solubility and infusion rate, this formulation still suffers from 
neutropenia related toxicities (91).  At 40-80 nm, these particles could be subject to both 
renal and hepatic filtration in addition to tumor extravasation (92).  The addition of vitamin E 
could be advantageous for a variety of reasons.  One shortcoming of PTX is several tumors 
are PTX resistant due to overexpression of P-glycoprotein (P-gp) (93).  The surfactant 
TPGS has been shown to act as an inhibitor for P-gp which could allow PTX to be more 
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effiective in these tumors (94).  Additionally, TPGS has been shown to have adjuvant toxicity 
with PTX, putatively by inducing caspase-8 (95).  If synergistic, this could require lower 
dosing of PTX compared to TAXOL thus decreasing the chance of neutropenia.  The use of 
intact drug in this formulation could make it more potent than typical prodrugs.  There is, 
however, an issue of stability as the particles may be prone to flocculation (96). 
Another formulation in phase III clinical trials is docosahexaenoic acid PTX (DHA-
PTX).  This formulation uses an ω-3 fatty acylated PTX at the 2’-OH to improve solubility in 
the TAXOL vehicle.   Formulation only requires 20% of the CrEL of TAXOL but still only 
yields 3% drug loading (97).  As with other 2’-OH derivatives, this derivative does not bind 
microtubules and will require hydrolysis for full toxicity (98).  After hydrolysis, the released 
DHA has been extensively shown to sensitize tumors to apoptosis (99-101).  While more 
tolerable than TAXOL, this formulation still suffers from neutropenia (102) due to the CrEL 
which demonstrates toxicity even at 20% of the dose.  An increase in half-life of the 
formulation is observed in humans despite the decrease in CrEL; 112 h as compared to 85 h 
for TAXOL (103).  LDL is known to efficiently bind unsaturated fatty acids, much better than 
albumin, and could provide a good vehicle for this molecule (104).  Partial binding of LDL 
could explain the slightly protracted half-life observed for DHA-PTX.  
Last is a technology involving a squalenoic acid derivative of PTX (sqPTX).  Initially 
this technology was developed by directly conjugating squalenoic acid to the hydrophilic 
nucleoside antagonist gemcitabine (difluorodeoxycytidine, dFdC) (105).  The resultant 
amphiphile showed self assembly into particles when diluted into water from a water 
miscible co-solvent.  This technology has now also been applied to the notoriously 
hydrophobic PTX (106).  Despite having no apparent hydrophilic headgroup, this monomer 
spontaneously aggregates into nanoassemblies of ~100 nm.  The addition of a 
triethyleneglycol or undecaethyleneglycol linker between the PTX and squalenoic acid 
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resulted in an increase in particle size up to ~300 nm.  Both were able to solubilize PTX to a 
concentration of 5 mg/mL.  The 100 nm sqPTX nanoassemblies were highly resistant to 
hydrolysis from pH 4-9 and were resistant to enzymatic hydrolysis in serum.  As with other 
2’-OH prodrugs, it is unable to bind microtubules thus requiring hydrolysis for activation, 
particularly as the conjugate experiences greatly reduced cytotoxicity compared to PTX.  
The PEGylated conjugates appear more cytotoxic and prone to hydrolysis in serum thus the 
cytotoxicity is most likely derived from higher PTX concentrations.  The 100 nm size may 
result in an increased liver and spleen accumulation due to RES uptake.   
The tumor localized sqPTX may not readily release PTX so a tumor specific 
cleavage of the sqPTX could be added to render a more potent formulation.  Considering 
this technology contains only two molecules of similar molecular weight, the drug loading is 
high at 70% and the manufacture inexpensive.  The sqPTX or one of the pegylated prodrugs 
could be built into a carrier such as a liposome as was done with sqdFdC (107), although 
the amphiphilic nature of sqdFdC may make it more amenable than sqPTX for this process.  
Derivatization of the liposomes with PEG could help shield the particles from detection by 
the RES (108).  Derivatization with targeting ligands on the distal end of PEG at tunable 
concentrations for increased avidity and receptor mediated endocytosis could facilitate 
intratumoral delivery.  Liposomes tend to offer a poor drug loading for PTX (~3%) and 
sqPTX would not see much improvement (109).    
7. Summary   
There are many different vehicles to formulate PTX for a more targeted and effective 
delivery and no single formulation exemplifies all the ideal characteristics of a delivery 
vehicle.  Natural carriers offer an interesting concept of using millions of years of biological 
evolution to design drug carriers that can be utilized in a myriad of ways.  There is very little 
control over the vehicle though as small changes can disrupt the natural tendencies of the 
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carrier.  These formulations tend to result in lower loading capacities and non-specific tissue 
destinations.  However, this approach is relatively inexpensive and effective provided the 
formulation can piggyback on the natural abundance of the carrier as opposed to requiring a 
recombinant carrier.   
Synthetic carriers offer the most control as they are limited only by synthetic 
potential.  This can allow higher loading capacity, endosomal escape mechanisms and more 
controlled and well-defined vehicles with the ability to titrate the level of drug and targeting 
ligand.  These macromolecules can be tailored to specific tumors based on easily 
exchangeable targeting ligands but may experience greater biological resistance due to the 
unnatural composition of the vehicles requiring the addition of a steric enhancer such as 
PEG.  This high degree of tunability comes at a cost.  The more functionalized the vehicle, 
the more taxing and expensive the synthesis.  
Lastly the lipid based technologies appear the most flexible having the ability to use 
natural carriers such as albumin or LDL, self-associate into vesicles or micelles or be 
integrated into synthetic carriers such as liposomes.  These formulations are perhaps the 
least expensive and easiest to manufacture but may experience issues with solubility.    
There is no express vehicle for targeted delivery or inherent release mechanisms.  As a 
result, these formulations may be more susceptible to non-specific sequestration or 
immunogenicity.  As all these ideas coalesce and develop, it will be interesting to see how 
the formulations adapt.  As the old adage says: the early bird gets the worm, but the second 
mouse gets the cheese. 
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CHAPTER II 
 
 
 
FATTY ACIDS AS THERAPEUTIC AUXILIARIES: REVIEW 
 
 
This chapter is being submitted for publication as a review to the Journal of Lipid Research 
and is formatted in the style of this journal. 
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1. Introduction  
When a drug is administered parenterally to a patient with a systemic disorder, it is 
immediately diluted throughout 6 liters of blood and potentially 18 L of interstitial volume.  
The site of action for the drug will typically encompass only a very small fraction of total body 
volume so concentrations of drug at the target will be minimal.  This dissipative nature of 
distribution poses a major problem for drug formulation leading to poor efficacy and high 
toxicity.  The nascent discipline of drug delivery endeavors to selectively alter the distribution 
of a drug for accumulation at the target site with diminution at non-specific sites.  This can 
be accomplished by utilizing a targeting mechanism that takes advantage of the specific 
milieu associated with the site of action.  Arguably the simplest method of targeting is to 
ascertain extant mechanisms by which the body naturally engages the tissue of interest and 
piggyback on them; for example, endemic hepatic expression of the asialoglycoprotein 
receptor (1) or the accumulation and consumption of serum albumin in arthritic joints (2).  
There are a myriad of delivery mechanisms, far too many to recount in a single review.  This 
review will focus on a subset of technologies utilizing fatty acids and triglycerides to improve 
the drug profiles for oral and intravenous administration.   
2. Formulations to Improve Oral Absorption 
Ingested lipids are highly insoluble and thus aggregate as micelles or submicron 
emulsions depending on composition.  The presence of these lipids in the intestines triggers 
the release of lipases, phosphoplipases and bile salts designed to hydrolyze triglycerides to 
diacylglycerides and monoacylglycerides releasing free fatty acids.  Glycerides and long-
chain fatty acids bind apical fatty acid binding proteins which deliver them to the 
endoplasmic reticulum (ER) of the enterocyte (3).  Shorter-chain fatty acids which exhibit 
higher solubility can bind monocarboxylic acid transporters (4).  Fatty acids can be 
transported to the portal vein for first-pass transfer to the liver, presumably via albumin 
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binding.  Alternatively, fatty acids can be reacylated into triglycerides and incorporated in 
chylomicrons which are delivered to the lamina propria and eventually the systemic 
circulation via the thoracic duct (3). These particles eventually mature into very low-density 
lipoprotein (VLDL) then low-density lipoprotein (LDL) or high-density lipoprotein (HDL) if they 
contain a large quantity of phospholipids.  Lymphatic absorption is a potentially useful 
mechanism for oral drug delivery to the systemic circulation as it bypasses the first-pass 
clearance of the liver altogether.  
2.1. Caprates  
One method to promote absorption of high solubility, low permeability molecules 
such as peptides is co-formulation with medium-chain fatty acids.  Caprates (C10:0) are 
believed to induce the transient opening of tight junctions facilitating paracellular absorption 
(5).  This process has been thoroughly demonstrated in Caco-2 cell culture (6), rat ilea (7), 
human ilea (8) and human colon biopsies (9).  While mechanistically complex, caprates and 
caprylates (C8:0) are believed to modulate tight junctions through phospholipase C induced 
release of Ca2+ and subsequent protein kinase C activation (6; 10).  This phenomenon is not 
observed for lauric acid (C12:0), although lauric acid too is believed to facilitate paracellular 
permeability (11).  These fatty acids are non-toxic and have been used successfully in many 
formulations (12).  High doses of sodium caprate alone have shown success for the 
absorption of 2’-O-methoxyethyl phosphorothioate antisense oligonucleotide gapmers 
against tumor necrosis factor-α achieving up to 13% bioavailability in humans (13). After 
absorption by the paracellular route, these molecules will be directed to the liver where a 
substantial portion may be extracted and degraded (14).  This is the most likely reason 
bioavailabilities remain low.  This idea has been streamlined through the Gastrointestinal 
Permeation Enhancement Technology (GIPET) (15).  The technology involves formulating a 
drug along with caprate and caprylate salts in an enteric soft gel.  Hydrophilic molecules like 
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peptides can quickly dissolve and diffuse through the intestinal lumen. Conversely, fatty acid 
salts will dissolve slower as they need to form micelles and possibly partition into bile salt 
emulsions before binding monocarboxylic acid transporters.  This process may be 
significantly slower, leaving the peptide in a hazardous environment with the highly 
proteolytic brush border enzymes (16; 17).  Application of the technology to low molecular 
weight heparin resulted in a doubling of the bioavailability, however this number is still quite 
low at approximately 8%.  The relative bioavailability of oral acyline, a gonadotropin 
hormone releasing antagonist, increased up to 16-fold in beagles (12) and showed activity in 
human volunteers (18) despite a very modest total bioavailability. 
2.2. Triglyceride Formulations  
Alternatively fatty acids can be used to elude first-pass metabolism by disguising a 
drug as a triglyceride.  Valproic acid was esterified at the sn-2 position on the glycerol 
backbone of lysophosphatidylcholine (19).  This molecule showed an ability to absorb 
across the gut lumen of rats and get packaged into chylomicrons for distribution to the 
lymphatics.  The technology was only able to achieve 9% bioavailability, 60% of which was 
due to lymphatic uptake.  The prodrug showed great resistance to lipases in vitro suggesting 
the issue may not be premature release of valproic acid for portal absorption.  The 
bioavailability appears dependent on several factors including the vehicle and the 
pre/postprandial state; in both cases, the presence of other lipids.  Formulation in peanut oil 
containing mostly palmitic (C16:0), stearic (C18:0), oleic (C18:1), and linoleic (C18:2) ester 
triglycerides promoted an increase in bioavailability. This is consistent with several other 
reports on long-chain triglycerides (20-22).  Alternatively, formulation with medium-chain 
triglycerides containing caprate and caprylate esters provided lower bioavailabilities.  The 
postprandial state also increased bioavailability compared with the starved state.  Standard 
rat chow is approximately 3% lipid, a vast majority of which are long-chain ω-fatty acids (23).  
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Common to both successful scenarios is the presence of long-chain triglyceride.  This 
observation has been noted in several other reports on lymphatically absorbed drugs as well 
(24-26).  Long-chain fatty acids have been associated with an increase in chylomicron 
formation in the Golgi apparatus of enterocytes (26) which should promote increased 
lymphatic delivery.  This methodology is amenable to both hydrophobic and hydrophilic 
small molecules.  It may be difficult, however, to apply to large hydrophilic molecules such 
as oligonucleotides or peptides due to the requisite membrane partitioning. 
2.3. Submicron Lipid Particles 
Submicron particles have been the subject of oral delivery recently due to their ability 
to carry a multitude of cargoes as well as their stability and targetability.  Being too large for 
significant paracellular absorption and lack of membrane permeability, these formulations 
require a different approach. The gastrointestinal tract is lined with a plethora of cells.  M 
cells are associated with a great deal of lymphatic innervations due to their function of 
sampling antigen from the intestines and passing it to the various antigen presenting cells 
within the lymph (27).  M cells have a thin glycocalyx and undergo frequent 
macropinocytosis.  Most commonly, particle absorption from the intestines is believed to 
occur through M cells and enterocytes, however, the endocytosis via enterocytes tends to 
be more destructive as M cells are devoid of lysosomes (28).  Targeting to Peyer’s Patches 
therefore presents an opportunity for higher lymphatic absorption of particles, particularly for 
inducing mucosal immunity.  The common mucosal immune system is an autonomous 
system of immunity protecting various mucosal organs, most notably the airway, gut, eye 
and genitals (29).  It is estimated about 80% of immunocytes are involved in the common 
mucosal immune system which is designed to protect the vast area of mucosal organs thus 
preventing systemic infection.  Commonly lipid particles are used for vaccine delivery due to 
the nature of lymphatic absorption of lipids (28).  Formulation of antigens in w/o/w multiple 
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emulsions containing squalene solubilized in saline with nonionic poloxamer surfactants 
allowed successful stabilization and delivery of a recombinant fusion protein from E. coli to 
Peyer’s Patches (30).  The fusion protein was unable to induce mucosal immunity 
subsequent to parenteral administration.  An orally viable tuberculosis vaccine was also 
developed for mucosal immunization (31).  When formulated with vegetable oil, this strain of 
the mycobacterium was stabilized in the gastrointestinal tract for absorption by M cells.  The 
lipid did not affect the efficacy of the vaccine even leading to greater protection when 
compared to the standard subcutaneous vaccine.   
3. Acylation of Therapeutic Molecules 
3.1. Albumin Binding 
Another approach to improve the therapeutic potential of peptides or proteins is by 
chemical modification with lipid moieties, either through a non-reversible or a reversible 
linkage. The lipids do not greatly affect the solubility of proteins, as they tend to be less than 
10% of the weight of the conjugate.  The lipids will most likely confer binding to serum 
proteins, specifically albumin. The merits for binding albumin as a drug carrier are well 
established (32; 33).  Albumin is a highly soluble protein which can confer solubility to 
hydrophobic drugs (34). It has a 19-day half-life in humans (35) and it is extremely abundant 
at 40-50 mg/mL in the vasculature. It can thus greatly retard elimination from the system.  
While the primary function of albumin is plasma expansion, it is also a carrier for fatty acids 
(36).  Albumin has 6-7 fatty acid binding sites for long-chain fatty acids (37) with dissociation 
constants in the nanomolar range (38).  The high affinity for the fatty acid binding sites is 
due to hydrophobic channels in the protein which cradle the aliphatic tail and cationic lysine 
or arginine residues at the apex of the channel which anchor the anionic carboxylate 
electrostatically (39; 40).  While it may be appealing to make a fatty acid conjugate of a drug 
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to utilize these pockets, the process can disrupt the electrostatic interaction at the surface of 
albumin. 
This high affinity is believed to be derived from two sources; hydrophobic interactions 
within the binding pocket which is primarily an entropy-driven process and the primarily 
enthalpy-driven electrostatic interactions with the anionic carboxylate of fatty acids.  To test 
this hypothesis, in an unpublished study, fluoresceinamine (FLA) was used as a drug 
surrogate and derivatized with a short diethyleneglycol linker.  The surrogate was 
subsequently attached to stearic acid (SA) and 3-pentadecylglutaric (PDG) acid via an 
amide as shown in Fig. II-1.  The only difference between the two molecules is the 
carboxymethyl group on the PDG acid which is hypothesized to anchor the conjugate to the 
protein as shown in Fig. II-2.  Both conjugates were subjected to isothermal titration 
calorimetry analysis at 30°C so the physicochemical paramet ers could be extracted.  The 
results show a 3.5 fold increase in affinity of PDG-FLA for delipidated human serum 
albumin.  This is derived from greater than twofold increase in enthalpy for the PDG 
conjugate compared to the SA conjugate.  However, the SA-FLA conjugate does show 1.5-
fold higher entropy compared to the PDG conjugate.  This could be a result of the 
carboxymethyl group on PDG preventing the proper seating of the conjugate in the binding 
pocket which could be remedied by increasing the tail length.  If true, the two conjugates 
should bind with comparable changes in entropy.  In this case, the calculated KA for the 
PDG-FLA conjugate would be approximately 125 fold higher than the FLA-SA conjugate due 
solely to retention of the carboxylate.   
3.2. Non-Reversible Lipidization 
In non-reversible methods of lipidization, peptide or proteins are typically modified 
with reactive fatty acid derivatives (e.g., fatty acid chloride or anhydride) at the α-amino or  
  
 
 
Figure II-1.   FLA conjugates for isothermal titration calorimetry 
soluble lipid conjugates were synthesized to determine the physicochemical parameters 
involved in albumin binding.  It is expected the fatty acid tail
contribute to positive entropy and the 
FLA, fluoresceinamine; PDG, 3
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Figure II-2. A schematic representation of the hydrophobic and electrostatic interactions 
involved in fatty acid-albumin binding (A).  The addition of a cargo such as fluoresceinamine 
may utilize only the hydrophobic interaction (B) or both hydrophobic and electrostatic 
interactions (C) depending on the modification chemistry. 
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the ε-lysyl amino groups, resulting in a stable amide bond (41-44).  One example is the non-
reversible lipidization of cystatin, a 13 kDa protein isolated from chicken albumen that is a 
known inhibitor of cathepsin-B.  Palmitoylation of the amino groups in this protein increased 
the membrane adsorptive proclivity of the protein for endocytic internalization and 
subsequent inhibition of lysosomal cathepsin-B (45).  This adsorption was determined to be 
dependent on the tail length of the fatty acid; increasing inhibition with increased tail length 
through stearic acid (C18:0) (46).  The maturation of the late endosome to lysosome would 
promote binding of the internalized cystatin molecules to cathepsins that are commonly 
found in these vesicles, assuming the palmitoylated protein survives the conditions of the 
lysosome.  While successful in vitro, membrane adsorption is non-specific, so systemic 
administration would conceivably benefit from the use of a carrier such as a liposome or 
lipoprotein for targeted accumulation and release. 
The seminal use of fatty acids for this purpose was myristoylated insulin detemir 
(LEVEMIR, Novo Nordisk, Denmark), which was approved by the FDA in 2005.  Insulin is a 
5.8 kDa polypeptide consisting of two chains linked by three disulfides.  In LEVEMIR, the 
polypeptide is myristoylated at the penultimate lysine residue (B29) (47).  Intact insulin 
polypeptide is terminated with threonine (B30), however in LEVEMIR the terminal threonine 
is removed.  It was found removal of the terminal threonine increased the affinity of 
LEVEMIR for albumin by approximately 3.5-fold (48).  The reason for this change in affinity 
is most likely due to how the molecule fits in the albumin binding pocket.  It is presumed the 
myristoyl amide as well as the whole lysine side chain fit in the pocket (48).  If true, the 
binding pocket could accommodate 20 atoms from the ω-position of the myristic acid to the 
α-carbon branching point of lysine.  Assuming the amide does not perturb binding in the 
pocket, this distance would be comparable to arachadic acid (C20:0) which is known to bind 
albumin (49).  Therefore, in LEVEMIR the C-terminus of the B chain sits at atop of the 
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pocket for electrostatic interactions with lysine or arginine.  If threonine is left at the C-
terminus, as with native insulin, the C-terminal carboxyl group would shift three atoms away 
from the binding pocket making formation of the salt-bridge less likely.  The result of this 
high affinity albumin conjugate is an increase in the half-life of insulin from 2.8 h to 8.8 h and 
no loss of activity when administered subcutaneously (47; 50).  
More recently, a second lipidized protein drug, liraglutide (VICTOZA, Novo Nordisk), 
was also approved by the FDA in 2010 (51).  VICTOZA is an analog of glucagon-like 
peptide (GLP-1), a 37-amino acid native peptide hormone that has a short pharmacological 
half-life of about 1 h.  VICTOZA differs from GLP-1 in the substitution of Lys34 to Arg34, and 
in the palmitoylation at Lys26 via a γ-glutamic acid spacer.  This modification results an 
improved pharmacokinetic profile, which is attributed to albumin-binding of liraglutide 
following administration.  Due to the long half-life of 11-15 h following subcutaneous 
injection, this lipidized analog is suitable for once-daily injection.  Another insulin analog, 
insulin degludec, is also in development by Novo Nordisk.  Similar to VICTOZA, insulin 
degludec is palmitoylated at an ε-lysyl amino group (B29) via a γ-glutamic acid spacer, and 
also has the terminal threonine removed.  Promising results from phase 2 clinical trials of 
insulin degludec have shown that subcutaneous administration three times a week produced 
glycemic control comparable to insulin glargine, an FDA approved long-acting basal insulin 
analogue in patients with type I (52) and type II diabetes (53).  
3.3. Reversible Lipidization 
The non-reversible lipidization of protein or peptide drugs has some limitations 
including the incompatibility between lipidization reagents and proteins/peptides in solution, 
and the loss of biological activity of the protein or peptide drug following modification. One 
technology to promote the half-life of the protein as well as maintain activity is reversible 
aqueous lipidization (REAL technology) (54).  This methodology involves the use of water-
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soluble acylation reagents thus circumventing the requirement of organic solvents used in 
non-reversible lipidization.  Additionally, in vivo reversible bonds (i.e. disulfide or pH-
sensitive bonds) are utilized to link the lipid moiety to the protein or peptide allowing 
regeneration of free protein or peptide following administration.  In this prodrug approach the 
disulfide bonds between cysteine residues in the protein are reduced, and the resultant free 
thiols are reacted with an activated disulfide of palmitoylated cysteine (55).  The weak 
reducing conditions of the serum can then slowly delipidate the modified protein allowing 
refolding and providing a controlled release of intact, bioactive protein.  Reversible 
lipidization using a pH-sensitive linkage involves the modification of free amino groups on 
the protein using an amine-reactive lipidization reagent.  The free protein is then slowly 
regenerated in vivo by hydrolysis at physiological pH (56).   
REAL technology has been applied to both peptides and proteins demonstrating 
increases in half-life.  When applied to Tyr3-octreotide (TOC), a ~1 kDa somatostatin analog 
for controlled delivery to the liver (57; 58), the half-life of 125I-labeled TOC and REAL-TOC 
increased from 4.2 h to 6.6 h (57).  When REAL was applied to the diuretic desmopressin 
(~1 kDa) (59), an increase in stability, potency and half-life was observed (60).  Similar 
improvements in pharmacokinetics, stability, and bioactivity have been observed for other 
proteins and peptides, including enkephalin (~0.5 kDa) (56), calcitonin (~3.4 kDa) (61) and 
interferon alpha (~20 kDa) (62). These benefits are most likely the result of binding to serum 
albumin.  Similar to insulin detemir, where palmitoylation is occurring through an amide of a 
terminal amino acid, the carboxylate on cysteine should be readily available for fulfilling the 
electrostatic interaction involved in albumin binding.  In support of this hypothesis, changing 
the REAL technology’s cysteine to cysteamine by decarboxylation or masking the charge 
with a methyl ester caused drastic decreases in the efficacy of the drug (63).  Both 
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modifications would eliminate the electrostatic interaction thus disrupting the high-affinity 
nature of albumin binding. 
In addition to the improved pharmacokinetic profile, lipidization has also been utilized 
as an approach to facilitate the oral delivery of protein and peptide drugs.  Two examples 
are the oral administration of calcitonin (61), and enkephalin (56).  The studies have shown 
that, compared to unmodified protein, the lipidized peptide drugs show improvements in the 
pharmacological activity as well as an increased maximal plasma concentration and AUC. 
Although the mechanism of enhanced oral absorption is unclear, lipidization is a viable 
approach in oral protein or peptide delivery. 
4. Lipoproteins as Carriers 
Aside from albumin, the other major family of natural lipid carriers is the lipoproteins.  
Lipoproteins are particles formed by the aggregation of triglycerides with less than 5% each 
of phospholipids, cholesterol and esterified cholesterol.  The whole complex is stabilized by 
a massive apolipoprotein (64).  The particles differ by composition, size and stabilizing 
protein yielding several classes; chylomicrons, VLDL, intermediate density lipoprotein (IDL), 
LDL and HDL (65; 66).  Primarily, VLDL/LDL/HDL are used as drug carriers.  VLDL 
receptors are commonly expressed in the capillary endothelium of muscle, heart and 
adipose tissues while LDL receptors tend to be expressed highly in the liver as well as many 
tumor tissues (65; 67).  HDL is also cleared primarily by the liver using the scavenger 
receptor SRB1 but is also heavily consumed by various cancerous cells (68).  The particles 
are stable with biological half-lives of several days, as well as an assumed protection from 
reticuloendothelial clearance (65; 69).  These particles provide competition for the binding of 
fatty acid substrates with albumin yielding comparable delivery potentials (70), although how 
long the complex remains intact in vivo is not clearly understood.   
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4.1. Lipoproteins in Gene Delivery 
In an exemplarily thorough study using various acylated siRNAs, it was found 
cholesterol and long-chain fatty acid, including stearic and behenic (C22:0) acids, 
conjugated siRNA show preferential binding to lipoproteins.  Conversely, myristoylated, 
palmitoylated and oleoylated siRNA bind exclusively to albumin (71).  The behenic and 
stearic derivatives bound HDL/LDL with “dissociation constants” of 100 µM and 300 µM, 
respectively.  The affinity was estimated by the ratio of bound/unbound cholesterol siRNA at 
given concentrations of lipoprotein.  Rather than a dissociation constant, this is better 
described as a partition coefficient as there is no specific binding site provided by the lipid 
aggregates but rather a propensity to partition into the particle.  This affinity is further 
confounded by the significant variability in composition of natural lipoprotein particles as 
opposed to the known and well characterized structure of albumin.  The behenic and stearic 
derivatives bound albumin with dissociation constants of approximately 200 µM and 
saturated the protein at 3.6 molar equivalents.  These values are in stark contrast to the free 
fatty acids which bind in the low nanomolar dissociation range with ~6 binding sites for 
stearic acid and 4 for behenic acid (38; 49).  Here again, the acylation chemistry eliminates 
the carboxylate moiety of all fatty acids so albumin binding affinity is expected to decrease.  
In this instance the loss of affinity is several orders of magnitude.   
A major concern for these complexes is in vivo stability.  The higher the “affinity”, the 
more the kinetics will mimic the kinetics of the carriers themselves.  These proteins are all 
catabolized throughout the body hence the respective ratio of catabolism in various systems 
is also important in terms of both efficacy and toxicity.  To answer these questions, the 
pharmacokinetics of a cholesterol conjugate of siRNA (Fig. II-3) was analyzed in mice using 
a dual label; 125I on the carrier (LDL, HDL, or albumin) and 32P on the cholesterol siRNA.  All 
three carriers demonstrated protracted half-lives whereas the conjugated siRNAs were  
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Figure II-3. The serum pharmacokinetics of a cholesterol derivative of 32P-labeled siRNA 
and various 125I-labeled serum components known to bind cholesterol.  Notice the relatively 
weak binding of the cholesterol-esterified siRNA to the serum components resulted in a 
significantly different profile compared to the carriers alone. Figure reproduced with 
permission from Nat Biotech (71). 
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completely cleared from the vasculature within 5 hours clearly reflecting the relatively low 
affinity of the conjugates for the carriers.  The biodistribution of cholesterol siRNA 
associated with the various carriers (Fig. II-4) shows a relatively uniform distribution 
throughout the body with a slight preference for the liver when bound to albumin or HDL.  
The LDL-bound cholesterol conjugate of siRNA by contrast shows minimal uptake in any 
tissue aside from the liver.   
4.2. Use of Lipoproteins in Targeting Specific Disease-State Cells 
Delivery via HDL has recently focused on cancerous cells.  The carriers used are 
recombinant, formed by suspending triglycerides with bacterially expressed Apolipoprotein 
A1 (Apo-A1) followed by heating and sonication (72).  The advent of Apo-A1 fusion proteins 
delineated two possibilities; the fusion protein could be therapeutic or, since the Apo-A1 sits 
at the interface, the fusion protein could include a targeting peptide (73).  In one instance, 
interleukin-11α was selected as a targeting peptide as the receptor is highly expressed in 
various cancer cell lines (74; 75). These technologies showed selective targeting to 
osteosarcoma masses and the addition of a cytotoxic peptide demonstrated efficacy in vitro.  
Efficacy was also demonstrated in vivo by fusing the cell penetrating TAT peptide from the 
human immunodeficiency virus to Apo-A1 carrying unmodified doxorubicin in the particle 
(73).  The particles release about 40% of the encapsulated doxorubicin within 5 h in normal 
saline containing 1% BSA.  Intratumoral injection of the rHDL showed efficacy of about 30% 
reduced tumor volume compared to the untreated control.  The results were comparable 
regardless of the presence of the TAT peptide or the rHDL itself, as free doxorubicin had 
comparable efficacy.  Considering the release rate, most of the doxorubicin is probably 
released quickly into the tumor.  To prevent this leakage or dissociation, the doxorubicin 
could be acylated, which would greatly increase the permeability into rHDL.  Commonly, ω-3 
fatty acids such as docosahexaeoic acid and linolenic acid are used as these not only  
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Figure II-4. Biodistribution analysis of albumin, LDL and HDL bound cholesterol-esterified 
[32P]-siRNA 4 h post tail-vein injection to mice.  Primarily the liver promotes the greatest 
release of the cholesterol conjugate from the lipoprotein carriers. Whereas albumin and HDL 
distribute the conjugate uniformly, LDL shows accumulation solely in the liver.  Figure 
reproduced with permission from Nat Biotech (71). 
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promote membrane permeability, but the ω-3 fatty acids show increased sensitization and 
even moderate toxicity to a variety of tumor cells (76-78).  A similar approach involved using 
recombinant Apo-A1Milano, a mutant with higher affinity for the HDL receptor (79).  These 
particles were loaded with 10-hydroxycamptothecin at up to 80% efficiency and showed a 
controlled release of 25% of the dose over 24 h when dialyzed in buffer.  Biodistribution in 
naïve mice shows primarily uptake in the kidneys and to a lesser extent the liver and spleen.  
Biodistribution was not yet performed on tumor bearing mice at the time of this writing. 
As with HDL, small synthetic LDL particles have been developed.  Coined “nano-
LDL”, the lipoprotein is a synthetic LDL receptor-binding domain coupled with a lipid-binding 
motif for the purpose of targeting cancerous cells; as an example glioblastoma multiforme 
(80).  The particle was formed with phospholipids and triglycerides as well as an oleic acid 
derivative of paclitaxel (PTX) (81).  The nano-LDL was able to solubilize the paclitaxel 
prodrug at 0.33 mg/mL and was shown to be very toxic to multiple glioblastoma multiforme 
cell lines expressing variable amounts of the LDL receptor.  It is suggested most neurons do 
not express high levels of the LDL receptor, which could make this vehicle very selective for 
glioblastoma multiforme cells in the brain.  The difficulty for LDL to cross the blood-brain 
barrier coupled with the ubiquitous expression of the LDL receptor systemically will preclude 
the use of this approach for parenteral administration.  Considering the apolipoprotein used 
is synthetic, this may simply require a change in the targeting motif for systemic cancers.  
Brain accumulation has been demonstrated using particles coated in serum ApoE or solid 
lipid nanoparticles coated with Tween 80 either of which may be incorporated into nano-LDL 
as well (82).   
Aside from cancer, LDL is often associated with atherosclerosis.  An excess of 
oxidized LDL, due to high concentrations of bloodborne lipid and cholesterol, leads to 
consumption in aortic vasculature by macrophages transforming them into foam cells (83).  
49 
 
Over time, more macrophages are attracted and the vasculature becomes congested and 
the excess cholesterol forms plaques.  Oxidized LDL may bind these plaques more tightly 
than native LDL facilitating undesirable accumulation of the lipoprotein (84) although this 
appears to decrease with progression of the disease.  This spontaneous accumulation of 
LDL at the target site makes it an ideal carrier for a therapeutic (85).  The steroid, 
dexamethasone, has been shown to prevent the transformation to foam cells.  Palmitoyl 
dexamethasone was then easily packaged into human LDL collected by ultracentrifugation 
from serum.  Biodistribution in atherosclerotic mice showed a decrease in distribution to the 
liver and increase to the target site, the aorta.  This persisted for 7 days and successfully 
protected early atherosclerotic lesions from worsening but it did not affect the underlying 
dyslipidemia.  Due to the difficulty in isolating large quantities of human LDL, the potential 
for transferring bloodborne pathogens and variability in particles, native LDL may be a 
difficult vehicle to use systemically (86).  Synthetic LDL-like emulsions, as in the case nano-
LDL, may prove more efficient for development (81; 87).  The lipid composition of the 
emulsion can be more properly controlled preventing off site targeting.  Monounsaturated 
fatty acids for instance tend to promote uptake and cholesteryl ester hydrolysis in 
macrophages (88). 
5. Concluding Remarks 
Employing fatty acids in delivering both large and small therapeutic agents has the 
potential to increase oral bioavailability as well as provide increased half-life, stability and 
permeability.  Large hydrophilic compounds may benefit from paracellular absorption using 
tight junction modifiers such as medium-chain fatty acids.  As this does not avoid hepatic 
first pass, in many instances, it does not greatly increase oral bioavailability but may be 
useful for macromolecules which would otherwise not be absorbed intact.  Targeting to the 
lymphatics via chylomicron partitioning in the ER of enterocytes can increase bioavailability 
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by circumventing hepatic first pass clearance although the process appears slow.  This may 
be the result of the slow formation of chylomicrons, a step that includes difficulty for fatty 
acid drug conjugate to become triglyceride.  Nonetheless, the formulation of a lymphatically 
absorbed drug with long-chain triglycerides, which are known to induce the formation of 
chylomicrons, increases the bioavailability of drug.  The oral route also provides a useful 
method for mucosal vaccination.  Targeted delivery of antigens to M-cells in the Peyer’s 
Patches allows uptake of the antigen by antigen presenting cells of the common mucosal 
immune system.  All these methods are designed to improve the profile of poorly 
bioavailable drugs and the results in most cases are very moderate.  The drugs then should 
be metabolically stable and highly potent to be successful. 
Parenterally administered drugs can be improved via acylation with various fatty 
acids.  Lipidized therapeutics exhibit greater half-lives allowing less frequent dosing.  The 
addition of fatty acids can disrupt the structure of larger therapeutics such as peptides or 
proteins rendering them less effective.  The increase in hydrophobicity can also lead to non-
specific adsorptive endocytosis.  Reversible lipidization can rectify these issues by slowly 
releasing intact peptides or proteins into the system.  This has been successfully applied to 
peptides and proteins of various sizes for both parenteral and oral administration.  Lipidized 
therapeutics can also be used to target albumin or serum lipoproteins.  This provides an 
alternative to the ubiquitous concept of pegylation for prolonging circulatory life.  Acylation is 
highly reversible due to copious amounts of esterases and lipases found throughout the 
body.  The chemistry is cost-effective, straightforward and the myriad of potential fatty acids 
allows tailoring of prodrugs for a specific purpose.   
A major concern for using protein complexation is the stability of the complex in vivo.  
In the case of albumin, the complex is concentration driven.  At the time of injection, 
complexation would be highly favorable.  After distribution, dissociation may become more 
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favorable.  Albumin deposits fatty acids throughout the body (36), most notably the 
parenchymal cells of the liver, heart and muscle.  This process can be highly efficient; 
cardiomyocytes extract 30-60% of the serum fatty acid content each pass although the 
mechanism of uptake is poorly understood.  The fatty acylated prodrugs that bind albumin 
behave differently than the natural substrates; certainly the drastic fluctuations in affinity are 
partly responsible. Possibly the complexes do not stay intact during FcRn, also known as 
Brambell receptor, recycling.  The prodrug may be ejected upon conformational change or 
the complex itself may not bind leading to degradation in the lysosome.   
Serum proteins are now the subject of investigation for tumoral delivery due to their 
passive accumulation via leaky endothelium.  These particles are large and driven mostly by 
convection which does not readily occur in the tumor; that is, they are not expected to 
penetrate tumor tissues effectively (89).  This may preclude binding to specific receptors 
expressed on tumor cells in the inner tissue, however decomposition in the periphery with 
subsequent drug release and diffusion may still be effective.  This process is believed to 
occur for albumin but may be slow compared to the catabolism of albumin throughout the 
rest of the body.  LDL and HDL have shorter half-lives than albumin and expression of their 
respective receptors are common.  This can have a significant impact on toxicity.  It is clear 
the complexes do not behave similar to the carriers.  The proteins have half-lives of multiple 
days whereas complexes are cleared much more rapidly.  Whether this is purely an issue of 
“affinity” or lack of protection by natural process such as FcRn recycling is not well 
understood.  Because these issues exist for synthetic drug delivery vehicles as well, the use 
of natural carriers may prove to be simpler, less-expensive and evolutionarily advantageous.  
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CHAPTER III 
 
 
A DICARBOXYLIC FATTY ACID DERIVATIVE OF PACLITAXEL 
 
 
 
This chapter is being submitted for publication to Bioconjugate Chemistry and is formatted in 
the style of this journal. 
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1. Abstract 
 TAXOL remains a potent chemotherapy for breast, lung and ovarian cancers, 
however the resultant hypersensitivity and neutropenia from the Cremophor EL in the 
formulation undermines the health of already debilitated patients.  To combat the poor 
solubility of the active ingredient, paclitaxel, a fatty diacid was synthesized for chemical 
ligation to the drug and subsequent binding of the conjugate to the highly soluble and 
ubiquitous protein, serum albumin.  The cyclized form of the lipid, 3-pentadecylglutaric 
(PDG) anhydride, is reactive to a variety of nucleophiles including the 2’-OH on paclitaxel.  It 
was discovered that the binding of the PDG derivative of paclitaxel to albumin resulted in the 
formation of 120 nm aggregates.  This was also found when paclitaxel alone was bound to 
albumin.  When injected intravenously to tumor bearing mice, the TAXOL formulation of 
paclitaxel was cleared rapidly, primarily to the liver, with a half-life of 7 hours.  In the case of 
the PDG derivative of paclitaxel, the drug is quickly distributed uniformly giving rise to a 23 h 
half-life after equilibration. This is comparable to the half-life of human serum albumin in 
mice supporting strong albumin binding in vivo.  The derivative is only moderately taken up 
by subcutaneously established tumors and is slowly hydrolyzed (<5% over 72 h) in serum, 
tumor cytosol and tumor tissue homogenate.  The PDG derivative is less cytotoxic than the 
parent paclitaxel thus requiring hydrolysis for full potency.  While superior to TAXOL in terms 
of serum pharmacokinetics, the PDG formulation should be comparable to the clinically 
approved paclitaxel-albumin product, ABRAXANE, another formulation that leads to 
aggregates of ~130 nm upon reconstitution.   
2. Introduction 
Paclitaxel (PTX) is a mitotic spindle inhibitor primarily indicated for ovarian cancer or 
in combination therapy for the treatment of non-small cell lung cancer and breast cancer.  
Notoriously insoluble, paclitaxel requires dissolution in ethanol and a surfactant Cremophor 
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EL in the commonly known product, TAXOL.  The large quantities of Cremophor EL lead to 
neutropenia and hypersensitivity in patients thus requiring a prophylactic regimen of 
dexamethasone1.  A second-generation formulation devoid of the surfactant uses the 
endogenous serum protein albumin as a vehicle.  Abi-007, also known as ABRAXANE, 
utilizes the intrinsic binding of PTX to albumin to entrap the drug in submicron particles of 
approximately 130 nm after co-nebulization1.  ABRAXANE showed itself superior to TAXOL 
in efficacy, half-life and toxicity and is currently indicated as a second line therapy for breast 
cancer2,3. 
At a vascular concentration of 40-50 mg/mL (0.6-0.75 mM) albumin is the most 
abundant serum protein4.  The high vasculature concentrations of albumin are maintained 
due to recycling via a protective protein known as the Brambell receptor (FcRn) which grants 
albumin a 19-day half-life in humans4.  This is an ideal characteristic sought by many 
synthetic vehicles for drug delivery in the literature today. The use of albumin as a drug 
carrier is not a novel concept, particularly for antineoplastics5.  It has been hypothesized 
albumin is the major sustenance for growing tumors6.  The high vascular concentrations 
beget high tumoral concentrations making albumin easily accessible as a nutritional 
source7,8.  This tumoral accretion is believed to proceed via passive filtration and 
sequestration in the tumor microenvironment via leaky endothelia5,9.  It has also been 
proposed albumin is actively transported into tumors via a selective overexpression of gp60 
(albondin) and the secreted protein acidic and rich in cysteine (SPARC) at the vicinal tumor 
endothelium10.  These proteins have been shown to facilitate transcytosis and paracellular 
transit of albumin across endothelia respectively.  The net result is a large concentration of 
albumin localized in a highly proteolytic tissue11,12.  Combined, these characteristics mold 
the paradigm of a desirable drug carrier. 
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The primary function of abumin is plasma expansion accomplished by maintaining an 
oncotic pressure across the vasculature with high (0.60-0.75 mM) intravasculature and lower 
(0.30 mM) extravasculature concentrations13.  Ancillary to expansion, albumin acts as a 
sponge for various metals, hydrophobic xenobiotics and fatty acids13.  Albumin is shown to 
have 6-7 binding sites for long chain fatty acids with Kd in the nanomolar range14,15.  These 
highly specific binding sites are due to hydrophobic channels in the protein which cradle the 
fatty acid tails.  The apex of these channels, at the protein/water interface, provides lysine or 
arginine cations which anchor the anionic carboxylate in place16,17.  Drug-fatty acid 
conjugation is typically accomplished through amides or esters consequently removing the 
electrostatic interaction of conjugate and protein18 such as in taxoprexin19 and squalenoyl-
paclitaxel20.  This will decrease the affinity of the conjugate for the protein as demonstrated 
through the myristoylated insulin, LEVEMIR21.  In the present study a new fatty acid, 3-
pentadecylglutaric (PDG) acid, is described that can be conjugated to a variety of 
nucleophiles.  The product of the reaction is a fatty acid conjugate that maintains an anionic 
carboxylate for the purpose of generating long-circulating albumin bound conjugates.  The 
technology is demonstrated through PDG-paclitaxel (PP), but could potentially be applied to 
any nucleophilic therapeutic. 
3. Experimental Procedures 
3.1. Materials   
All chemicals involved in the synthesis were purchased from Sigma-Aldrich at >98% 
purity and used without further purification.  Delipidated human serum albumin was also 
purchased from Sigma-Aldrich at 96% purity.  All solvents were purchased from BDH and 
were ACS grade or higher.  Paclitaxel was purchased from AK Scientific (Union City, CA) 
and used without further purification.  CT26 murine colon carcinoma cells were obtained 
from ATCC and grown at 37°C at 5% CO 2 in RPMI-1640 media supplemented to 10% fetal 
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bovine serum, 1% penicillin and streptomycin.  Cells were passaged twice before 
implantation to mice.  Tritium labeled PP and PTX were synthesized by Moravek 
Biochemicals (Brea, CA) at a specific activity of 11 Ci/mmol and 36 Ci/mmol respectively 
with tritium substitutions at the ortho positions on the benzamide ring of paclitaxel.  All 
animals were female BALB/c 6-8 week old, 18-20 g mice from NCI.  Mice were allowed 1 
week acclimation prior to beginning studies.   All animal studies were performed under 
approval of the University of North Carolina Office of Animal Care and Use in accordance 
with the standards set forth by the Institutional Animal Care and Use Committee. 
3.2. Spectroscopy  
Mass spectra were obtained on an Agilent 1100-DAD-FLD Ion trap ESI mass 
spectrometer in MeOH or MeCN. 1H NMR and 13C NMR spectra were recorded on an Inova 
400 MHz NMR at 30° C in CDCl 3 or CD3OD; chemical shifts are referenced to TMS (δ 0.00 
ppm) for 1H NMR and CDCl3 (δ 77.23 ppm) or CD3OD (δ 49.15 ppm) for 13C NMR.  Spectral 
data for all intermediates are provided in the Appendix as Figs. A-8-A-21.  UV/Vis 
spectrophotometry was carried out on a Shimadzu UV-2401PC.  Scintillation counting was 
conducted on a Packard Tri-Carb 2900TL. Dynamic Light Scattering was conducted on a 
Malvern Zetasizer Nano ZS detecting 173° non-invasive  backscatter.   
3.3. Synthesis of Ethyl-(E)-octadec-2-enoate (1)  
A suspension of pyridiniumchlorochromate (PCC), 7.98 g, (37 mmol, 1.5 eq) and 
NaOAc, 3.06 g, (37 mmol, 1.5 eq) was stirred in 250 mL anhydrous DCM in a two-neck flask 
equipped with an addition funnel and a condenser under nitrogen atmosphere.  After 5 mins 
of stirring at room temperature, the solution became black.  Hexadecanol, 6 g, (24.7 mmol, 1 
eq) was dissolved in 125 mL anhydrous DCM and added to the reaction via the addition 
funnel at room temperature over 1 h.  The mixture was stirred at room temperature for 
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another 2 h and (carboethoxymethylene)triphenylphosphorane, 12.10 g, (34.7 mmol, 1.4 eq) 
was added through the sidearm and the solution refluxed for 48 h.  The reaction mixture was 
adsorbed on a plug of silica and eluted with EtOAc to remove the PCC and NaOAc.  The 
eluent was concentrated and re-dissolved in 5% EtOAc in petroleum ether then eluted on 
silica gel with the same.  The product was recovered as a colorless oil which solidifies upon 
cooling (6.54 g, 85% yield over two steps). This specific product has been synthesized and 
characterized before so only the 1H NMR and MS is provided22. 1H NMR (400 MHZ, CDCl3) 
δ 6.96 (m, 1H, HC=CH-CH2), 5.81 (d, 1H, HC=CH-CH2), 4.18 (m, 2H, O-CH2CH3), 2.19 (q, 
2H, γCH2), 1.54 (s, 1H, -CH2-CH-CH2), 1.45 (t, 2H, δCH2), 1.30-1.26 (m, 29H, -CH2CH2-,-
OCH2CH3), 0.88 (t, 3H, CH3).  ESI-MS (pos, MeOH): 333.5 [M+Na]+. 
3.4. Synthesis of 3-Pentadecyldiethylglutarate (2)   
Sodium metal, 111 mg, (4.83 mmol, 3 eq) was stirred in 10 mL dry EtOH at 0°C until 
the solution became clear.  To this was added diethylmalonate, 386 mg, (367 µL, 2.42 
mmol, 1.5 eq) and (1), 500 mg, (1.61 mmol, 1 eq) in 5 mL dry EtOH.  The solution was 
refluxed for 3 h and cooled to ambient.  The solution was concentrated, diluted with water 
and extracted with EtOAc.  The EtOAc layer was dried over magnesium sulfate, filtered and 
concentrated to a colorless oil.  The oil was dissolved in DMSO at a concentration of 6 mL/g 
and to it was added 1 equivalent of H2O and 2 equivalents of NaCl and the solution refluxed 
for 5 h.  Dilution with water and extraction into EtOAc yielded a colorless oil.  The product 
was purified on silica gel eluting with 5% EtOAc in petroleum ether (603 mg, 94% over two 
steps).  1H NMR (400 MHz, CDCl3) δ 4.13 (q, 4H, -OCH2CH3), 2.34 (m, 5H, -CH2-CH-CH2-), 
1.33-1.24 (m, 34H, -CH2CH2-,-OCH2CH3), 0.88 (t, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 
172.8, 60.4, 38.9, 34.2, 32.4, 32.1, 29.8, 26.8, 22.9, 14.4, 14.3. ESI-MS (pos, MeOH) m/z 
399.7 [M+H]+, 421.8 [M+Na]+, 437.8 [M+K]+. 
65 
 
3.5. Synthesis of 3-Pentadecylglutaric acid (3)   
To a solution of (2), 1.06 g, (2.66 mmol, 1 eq) in 15 mL MeOH was added 30 mL 2 N 
NaOH.  The mixture was heated to a reflux with stirring for 6 h causing the suspension to 
become clear.  The solution was cooled to ambient, acidified to pH 1 with concentrated HCl 
and extracted with methyl tert-butyl ether.  The organic layer was dried with magnesium 
sulfate, filtered and concentrated.  The product was collected as a white solid (900 mg, 
99%).  The compound was pure by TLC 10% Me2CO in petroleum ether. 1H NMR (400 MHz, 
CD3OD) δ 2.33-2.27 (m, 5H, CH2-CH-CH2), 1.37-1.29 (m, 28H, -CH2CH2-), 0.90 (t, 3H, -
CH3). 13C NMR (100 MHz, CD3OD) δ 176.7, 39.6, 35.2, 33.5, 33.3, 30.9, 27.8, 23.9, 14.6.  
ESI-MS (neg, MeOH) m/z 341.7 [M-H]-.  
3.6. Synthesis of 3-Pentadecylglutaric anhydride (4)   
The intermediate (3), 900 mg, (2.63 mmol, 1 eq), was suspended in 3 mL EtOAc and 
heated gently until dissolved.  To the solution was added trifluoroacetic anhydride (TFAA), 
773 mg, (0.513 mL, 3.68 mmol, 1.4 eq) and the solution was capped and heated to 37°C 
with shaking for 2 h.  The solution was evaporated and the solid taken up in hot EtOAc and 
precipitated with cold petroleum ether followed by cooling the suspension to -18°C.  
Filtration of the solid and drying under vacuum produces the product as a fluffy white 
powder in quantitative yield (853 mg, 100%). 1H NMR (400 MHz, CDCl3) δ 2.89 (dd, 2H, 
CH2-CH-CH2), 2.43 (dd, 2H, CH2-CH-CH2), 2.19-2.12 (m, 1H, CH2-CH-CH2), 1.40-1.26 (m, 
28H, -CH2CH2-), 0.88 (t, 3H, -CH3).  13C NMR (100 MHz, CDCl3) δ 167.1, 36.3, 34.7, 32.1, 
29.8, 28.9, 26.5, 22.9, 14.3. ESI-MS (pos, MeCN) m/z 325.4 [M+H]+, 347.6 [M+Na]+.  
3.7. Synthesis of Paclitaxel-2’-O-3-pentadecylhemiglutarate (5)   
Intermediate (4), 21 mg, (64.5 µmol, 1.1 eq), PTX, 50 mg, (58.6 µmol, 1 eq) and 4-
dimethylaminopyridine (DMAP), 0.7 mg,(5.86 µmol, 0.1 eq) were dissolved in 0.8 mL dry 
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pyridine and the reaction stirred overnight at room temperature.  The reaction was 
concentrated by rotary evaporation and the solids taken up in DCM and washed with 0.1 N 
HCl.  The DCM was dried with magnesium sulfate, filtered and concentrated.  The solid was 
adsorbed onto silica and eluted with 1:1 EtOAc in petroleum ether supplemented with 1% 
AcOH.  The product was recovered as a white solid. (58.4 mg, 85%).  1H NMR (400 MHz, 
CDCl3) δ 8.12 (d, 2H, ArH), 7.75 (d, 2H, ArH),  7.62-7.24 (m, 11H, ArH), 6.29 (s, 1H, C10), 
6.24 (t, 1H, C-13), 5.99 (dd, 1H, C-3’), 5.68 (d, 1H, C-2), 5.50 (d, 1H, C-2’), 4.97 (d, 1H, C-
5), 4.40 (dd, 1H, C-7), 4.29 (d, 1H, C-20), 4.20 (d, 1H, C-20), 3.80 (d, 1H, C-3), 2.56-2.50 
(m, 1H, -CH2-CH-CH2-), 2.45 (s, 3H, OAc), 2.40-2.28 (m, 3H, -CH2-CH-CH2-, C-6α), 2.24-
2.13 (m, 7H, OAc, C-14, -CH2-CH-CH2-), 2.00-1.85 (m, 4H, C-18, C-6β), 1.66 (s, 3H, C-19), 
1.26-1.19 (m, 31H, -CH2CH3, C-17), 1.13 (s, 3H, C-16), 0.88 (t, 3H, -CH2CH3). 13C NMR 
(100 MHz, CDCl3) δ 204.0, 176.7, 171.9, 171.5, 170.2, 168.3, 167.7, 167.2, 142.9, 137.1, 
133.8, 133.0, 132.2, 130.5, 129.0, 127.1, 84.7, 81.3, 79.2, 75.8, 75.3, 74.4, 72.2, 58.7, 53.1, 
45.8, 43.4, 38.0, 35.7, 34.1, 32.2, 29.9, 29.7, 27.1, 22.9, 22.3, 21.0, 15.0, 14.3, 9.8. ESI-MS 
(pos, MeOH) m/z 1201.1 [M+Na]+. 
3.8. Cytotoxicity of PP  
The cytotoxicity of PP and PTX were analyzed by the NCI as part of the NCI-60 DTP 
Human Tumor Cell Line Screen23.  Various human cancer cell lines were plated at 5000-
40000 cells/well and treated with five concentrations of PP or PTX from 10 nM to 100 µM.  
The effect on cell growth is compared to cell lines fixed at t=0 and the untreated control via 
the Sulforhodamine B test.  Dose response curves were then generated across 60 cell lines 
and the 50% growth inhibition (GI50), total growth inhibition (TGI) and 50% lethal 
concentration (LC50) values were determined for each cell line. 
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3.9. Biochemical Stability of PP   
CT26 cells were grown in a flask to confluency (~4 million cells) and the cells 
washed then scraped off the flask and suspended in 5 mL Hank’s balanced salt solution 
(HBSS).  The suspension was then centrifuged at 600 x g for 5 minutes at 4°C.  The 
supernatant was removed and replaced with 0.5 mL fresh HBSS.  The cells were 
homogenized on ice using a Potter-Elvehjem homogenizer attached to an Hitachi 12-Volt 
3/8" cordless peak lithium ion micro driver drill at 1300 rpm while continuously plunging for 
15 minutes.  The suspension was centrifuged at 6000 x g to pellet the cell debris, the 
supernatant diluted to 1 mL and separated into 10 x 100 µL aliquots and stored at -18°C 
until use.  Prior to use, the aliquots had to be recombined and diluted twofold to attain the 
volume necessary to run an experiment in duplicate. 
An 8-week old female BALB/c mouse was inoculated with 5 x 105 CT26 cells on the 
right flank and the tumor allowed to grow to ~1000 mm3, as calculated using the volume of 
an ellipsoid (see III.14).  At this point, the mouse was anesthetized with 0.1 mL 100 mg/mL 
ketamine administered intraperitoneally (i.p.) with subsequent cervical dislocation.  The 
tumor mass was harvested, washed with PBS and blotted dry.  The tumor was weighed and 
diluted with 2 volumes of PBS.  The suspension was coarsely homogenized on ice using a 
PowerGen® 700 tissue homogenizer at speed 7 for 5 minutes until no lumps of tissue 
remained.  The tissue homogenate was mixed thoroughly, separated into 1 mL aliquots and 
stored at -18°C until use. 
For serum preparation, 8 female 8-week old BALB/c mice were anesthetized with 0.1 
mL 100 mg/mL ketamine i.p. until unresponsive to toe pinching.  The mice were then 
exsanguinated by cardiac puncture with subsequent cervical dislocation.  The whole blood 
was pooled and stored at 4°C overnight.  The fibrin cl ot was pelleted by centrifuging the 
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suspension at 6000 x g at 4°C and the supernatant remov ed and separated into 500 µL 
aliquots. 
Standard curves were generated by combining PP (160-1 µM) and PTX (1–160 µM) 
in EtOH with aliquots of the test matrix (serum, cell or tissue homogenate) at a 1:10 (v/v) 
ratio respectively.  The matrices were then diluted with equal volumes of 1 N HCl and 
precipitated with 8 volumes of MeCN containing 500 nM docetaxel as internal standard.  To 
examine the stability of the PP, the highest stock of PP in EtOH (160 µM) was diluted into 
each matrix in duplicate at a (v/v) ratio of 1:10.  The matrices were warmed to 37°C in a 
waterbath and shook vigorously.  Each matrix was sampled at given times by taking 20 µL 
samples and adding 20 µL 1N HCl followed by 160 µL MeCN containing 500 nM docetaxel.  
The precipitate was pelleted at 800 x g for 2 minutes and the supernatant removed for 
analysis.   
The supernatant was run on an Aquasil C18 reversed phase column (2.1 x 50 mm) 
with 5 µm particles and 80 Å pore size using 20 µL injections.  The eluent was a binary 
gradient containing 0.1% formic acid in water (A) and 0.1% formic acid in MeOH (B).  The 
gradient began with 1 minute of 30% B followed by a linear increase over 2 minutes to 95% 
B.  The eluent was then held constant at 95% B for 15 sec followed by a 30 sec linear 
decrease down to 30% B and 30 sec re-equilibration at 30% B. The solvent pump used was 
a Shimadzu SCL-10Avp operating at a flow rate of 0.75 mL/min with an injection loop of 100 
µL.  Analysis was by an API 4000 Triple Quadrupole LC/MS/MS mass spec (AB Sciex 
Instruments) scanning for parent to daughter transitions of 854-525 m/z (PTX) and 854-525 
m/z (PP) in negative mode.  The 1178-854 transition for PP was inconsistent so the 
daughter paclitaxel and its subsequent daughter fragment were used for analysis for both 
standard curve and stability study.   
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Concentrations were determined by integrating the area under the curve for the 
various peaks and assigning a concentration per the standard curves.  The extraction 
efficiencies of both PP and PTX were determined for the three matrices.  This was done by 
spiking the individual matrices in duplicate with radiolabeled stock of either PP or PTX.  
Aliquots of the stock were weighed out and analyzed by liquid scintillation counting (LSC) to 
determine the concentration.  Next the matrices were extracted with 1 volume of 1 N HCl 
and 4 volumes of MeCN.  The samples were centrifuged at 16.1 x 1000g for 5 mins and the 
supernatants quantiated by LSC.  Efficiencies were calculated as a ratio of concentration 
found from the extraction over the initial concentration in the matrix x 100.   
3.10. Formulation of PP with Albumin   
A 10x stock solution of PP in t-BuOH is made and confirmed via UV 
spectrophotometry after dilution in EtOH (ε228=30,593 M-1cm-1, EtOH).  The PP stock is then 
added to a 5% (w/v) stock of delipidated HSA in water (Sigma, A1887) at a 1:10 volume 
ratio of EtOH:HSA (ε278=39,800 M-1cm-1, water)24 which immediately causes turbidity due to 
precipitation of PP.  The sample was shell-frozen and lyophilized over 24 h.  The sample 
was then reconstituted in 0.1 M phosphate buffer at pH 7.4 and filtered through a 0.22 µm 
PVDF filter. (Millipore Billerica, MA)  If the stock contains [3H]-PP, it is quantified via LSC.  If 
the stock is not radiolabeled, it is extracted by diluting with one volume of 1 N HCl and eight 
volumes of MeCN then added a quantity sufficient of EtOH to make the volume 5 mL in a 
volumetric flask and analyzed via UV-Vis.  The loading efficiency of PP is inconsistent with a 
maximum loading of about 50% for higher doses. 
3.11. Formulation of PTX as TAXOL   
Paclitaxel solutions were prepared at either 6 mg/mL or 9.4 mg/mL in 1:1 (v/v) 
EtOH:Cremophor EL. The drug concentration was confirmed by diluting with EtOH and 
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analyzing by UV abosrobance (ε228=29.800 M-1cm-1, EtOH).  The organic stock was diluted 
5-fold with PBS to produce a concentration of about 1.2 mg/mL or 1.9 mg/mL respectively 
immediately prior to injection. 
3.12. Dialysis of PP-Human Serum Albumin (HSA) Complex   
To determine whether the PP-HSA complex would dissociate over time, the complex 
was dialyzed against delipidated human serum albumin in phosphate buffer to create sink 
conditions.  Dialysis was conducted across a Spectra Por 12-14 kDa MWCO regenerated 
cellulose dialysis membrane with 500 µL fiberglass compartments.  A 0.1 M phosphate 
buffer pH 7.4 containing 0.01% NaN3 was diluted 10:1 (v/v) with EtOH.  This EtOH-
containing buffer was saturated by shaking with solid PP for 24 h at 37°C then cooled to 
ambient and filtered through a 0.22 µm PVDF filter.  Albumin was dissolved in phosphate 
buffer without EtOH at concentrations of 40 mg/mL and 10 mg/mL as confirmed by UV.  
Finally a stock solution of [3H]-PP in EtOH was made to a concentration of 15 mg/8.63 x 107 
dpm/mL.  The PP stock was added to the albumin stocks in a 1:10 (v/v) ratio and the stocks 
were filtered through a 0.22 µm PVDF filter.  These stocks were analyzed by LSC for PP 
content and UV for HSA content. 
The saturated solution of [3H]-PP in 0.1 M phosphate buffer pH 7.4 was dialyzed 
against blank phosphate buffer for 5 h with sampling of both compartments every hour to 
determine how quickly free PP could establish equilibrium.  The albumin solutions loaded 
with PP were sampled after shaking for 24 h at 37°C a nd the compartment replenished with 
fresh aliquots of the initial contents.  After another 24 h of shaking at 37°C, all contents were  
analyzed.  Analysis involved weighing 200 µL aliquots of the sample into scintillation vials 
and adding 5 mL Ultima Gold scintillation cocktail followed by LSC (Table III-1). 
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Table III-1.  Dynamic dialysis of [3H]-PP-HSA against delipidated HSA.  [3H]-PP-HSA in 
compartment A was dialyzed against delipidated HSA in compartment B across a 
regenerated cellulose membrane with a MW cutoff of 12-14 kDa (Spectra Por).   After 48 h, 
only 3% of PP bound in the form of PP-HSA had dialyzed across the membrane. As shown 
by the first 5 entries, free PP can diffuse freely across the membrane within hours 
suggesting dissociation of PP from the PP-HSA complex is very slow. 
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3.13. Pharmacokinetics/Biodistribution of [3H]-PP-HSA and [3H]-TAXOL   
Female, 6-8 week old BALB/c mice were administered 5 x 105 CT26 murine colon 
carcinoma cells in 0.1 mL HBSS on the right flank.  When the tumors were ~1000 mm3, the 
mice received the radiolabeled dose as formulated in 4% HSA in 0.1 M phosphate buffer 
(0.08 mg PP equiv to 0.058 mg PTX/1.75 x 107 dpm/0.1 mL) or as TAXOL (0.147 mg 
PTX/2.22 x 106  dpm/0.1 mL) via the tail vein. 
Approximately 5 minutes prior to the timepoint, the mice were injected i.p. with 0.1 
mL 100 mg/mL ketamine.  Once unresponsive to toe pinching, the mice were exsanguinated 
via cardiac puncture with subsequent cervical dislocation.  The whole blood was quickly 
weighed as 200 µL aliquots in triplicate.  The target organs were harvested, washed with 
PBS, blotted dry and small (~100 mg) pieces excised, weighed and stored in scintillation 
vials in duplicate.  The target organs include the liver, lungs, heart, kidneys, spleen, tumor 
and injection site on the tail. 
To the whole blood aliquots was added 1 mL of Solvable® tissue solubilizer. (Perkin 
Elmer, 6NE9100)  The sample was incubated for 1 hour at 55°C turning brownish-green.  To 
this was added 100 µL of 0.1 M ethylenediaminetetraacetic acid disodium followed by 300 
µL 30% H2O2 in 100 µL aliquots.  The reaction can be quite vigorous and was allowed to 
continue at room temperature until the foaming subsided.  The samples were then heated to 
55°C for an additional hour yielding clear to slightl y yellow solutions.  The samples were 
cooled to ambient and 15 mL Ultima Gold scintillation cocktail was added and mixed 
thoroughly.  The samples were rested in the liquid scintillation counter for 1 h to adapt to 
light and temperature prior to counting. 
To the organs was added 1 mL of Solvable® followed by heating to 55°C for 2 h.  
Once dissolved (yellow to slightly yellow) the samples were cooled to ambient and 200 µL of 
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30% H2O2 was added in 100 µL aliquots.  The samples were then heated to 55°C again for 
30 min.  The samples were cooled to ambient and 15 mL Ultima Gold scintillation cocktail 
was added and thoroughly mixed.  The samples were rested in the LSC for 1 h to adapt to 
light and temperature prior to counting.   
Aliquots of PP stock were weighed in triplicate and analyzed via liquid scintillation 
counting. A tumor bearing mouse was then anesthetized with 0.1 mL 100 mg/mL ketamine 
i.p. and exsanguinated via cardiac puncture.  The mouse was sacrificed and the target 
organs harvested.  Aliquots of 175 µL, 200 µL and 225 µL of blood were weighed and 
spiked with a weighed amount of PP stock (~1 x 104 dpm).  Additionally, ~75, 100 and 125 
mg samples of organs were washed, blotted dry and weighed then spiked with a weighed 
amount of PP stock (~1 x 104 dpm).  The samples were then processed in the same fashion 
as the unknown samples.  The counting efficiency was calculated as the ratio of dpm in the 
organ sample / calculated PP stock dpm x 100.  The efficiencies were plotted as a function 
of organ or blood mass and fitted with a linear regression.  The calculated efficiency was 
then used to correct the counts for the unknown samples based on blood volume or organ 
mass. 
3.14. Pharmacodynamics of PP-HSA and TAXOL   
Female, 6-8 week old BALB/c mice were administered 5 x 105 CT26 murine colon 
carcinoma cells in 0.1 mL HBSS on the right flank.  The mice were separated into groups; 
mice that developed tumors quickly and mice that developed tumors after a delay.  When 
the quickly developed tumors were 600-700 mm3 (n = 4 mice/group), the mice received their 
first dose.  About 10 days later, the delayed tumors (n = 2 mice/group) were given their first 
injections with average tumor volumes of 400-700 mm3.  The dosing schedule for PP (7 
mg/kg with respect to PTX) and PTX (10 mg/kg) was every 3 days for 15 days25.  Efficacy 
was analyzed via tumor size measurements every three days.  Tumors were measured 
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directly using digital calipers and the volume quantitated as an ellipsoid using the formula (l 
x w2 x 


) where width is the longest measured diameter.  Both formulations were compared 
to a control group given injections of PBS on the same dosing schedule.  Mice were 
sacrificed when the width of the tumor exceeded 2 cm.  Results were compared using a 
one-way ANOVA for n=6 mice per group. 
4. Results 
4.1. Chemistry   
The synthesis of 3-alkylglutaric anhydrides has already been demonstrated26.  This 
synthetic scheme was shortened and modified (Scheme III-1).  Hexadecanol was oxidized 
to palmitaldehyde using PCC and subsequently subjected to Wittig olefination using the 
ylide (carboethoxymethylene)triphenylphosphorane22.  The α,β-unsaturated ethyl ester was 
then be used as a Michael acceptor for sodiomalonate under refluxing conditions27.  The 
resultant triester is then decarboxylated and saponified to the 3-alkylglutaric acid27.  
Dehydration of the diacid can be affected with TFAA in EtOAc at 37°C 28.  PDG anhydride 
itself is reactive to amines and alcohols thus it could react with paclitaxel at three 
positions29,30.  Paclitaxel is known to be reactive to glutaric anhydride at the 2’-OH position at 
room temperature.  The 7-OH is only reactive under heated conditions and the 1-OH is 
unreactive29,30.  Mixing PDG and PTX in pyridine with a catalytic amount of DMAP allows 
complete reaction at room temperature in 24 h (Scheme III-2).  
4.2. Pharmaceutics 
Paclitaxel is very poorly soluble (~10 ug/mL)31 and adding a fatty acid to this 
molecule only exacerbates the issue.  The solubility of PP was calculated using a radiolabel 
at about 0.36 µg/mL (0.26 µg/mL PTX) in 0.1 M phosphate buffer at pH 7.4, room 
temperature.  In the presence of HSA, the solubility of PP should increase dramatically to a 
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Scheme III-1. Synthesis of PDG anhydride from hexadecanol.  PCC, 
pydridiniumchlorochromate; NaOAc, sodium acetate; TFAA, trifluoroacetic anhydride 
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Scheme III-2. Synthesis of PP.  The reaction is performed at room temperature as heating 
the solution will cause a mixture of isomers with the 7-ester. H* corresponds to the sites 
replaced with [3H] in the radiolabeled compounds synthesized by Moravek Biochemicals. 
(Brea, CA). DMAP, 4-dimethylaminopyridine. 
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theoretical maximum of the number of fatty acid binding sites multiplied by the concentration 
of HSA.  This would be a solubility of about 3.6 mM (3.07 mg/mL with respect to PTX) 
conservatively assuming a 40 mg/mL physiological solution of albumin and 6 fatty acid 
binding sites.  After two weeks of equilibration, the concentration of PP with respect to PTX 
(54 µg/mL) was substantially less than the theoretical maximum (Fig. A-1). 
To improve solubility, PP was dissolved in a water miscible co-solvent, t-BuOH, and 
introduced to aqueous albumin at 10% (v/v).  We found albumin to be structurally stable to t-
BuOH at this concentration via circular dichroism analysis (Fig. A-3).  This is unsurprising as 
other small alcohols at this concentration do not perturb its secondary or tertiary structure32.  
Distilled water was chosen as a solvent as electrolytes tend to create an unfavorable 
environment for PP leading to increased precipitation.  After loading, the suspension was 
shell frozen and lyophilized to a cake which was reconstituted in an isotonic system.  
Filtration of the suspension yields a clear blue solution indicating particles due to Tyndall 
scattering.  Analysis using Dynamic Light Scattering showed aggregates of 120 nm 
diameter. 
The slow equilibration and poor solubility of PP precluded determination of the 
dissociation constant via conventional methods such as isothermal titration calorimetry or 
equilibrium dialysis.  Instead, the PP-HSA complex was formed and the stability of the 
complex was examined.  Dialysis of a PP solution over 5 h showed a rapid equilibrium could 
be attained within this time period.  In contrast, dialysis of the PP-HSA complex against 
comparable concentrations of delipidated HSA, which should act as a sink for free PP, 
showed only about 3% of PP was released from the complex over two days at 37°C for 5% 
and 1% concentrations of HSA (Table III-1). 
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4.3. Cytotoxicity   
The IG50, TGI and LC50 were determined for PP and PTX via the NCI-60 DTP Human 
Tumor Cell Line Screen.  The results for all three values consistently showed a superior 
cytotoxicity of PTX to PP by at least an order of magnitude up to several orders.  For 
simplicity, representative data on the TGI is presented (Table III-2).  Due to the large 
number of cell lines, only two were selected from each cancer type which demonstrated the 
greatest toxicity for PTX and PP. 
4.4. Biochemical Stability   
Prior to the experiment, stock solutions of [3H]-PP and [3H]-PTX in EtOH were 
introduced to various milieu at a 1:10 (v/v) ratio.  Subsequent to incubation for a given 
period of time, samples were taken and extracted with 1 volume of 1 N HCl and 8 volumes 
of MeCN, vortexed and pelleted.  For undiluted murine serum, PP and PTX were 
quantitatively extracted.  For CT26 cytosolic fraction, PP was extracted at 97% efficiency 
and PTX at 91%.  For CT26 tissue homogenate, PP was extracted at 90% efficiency and 
PTX at 94% efficiency.  Results of the stability study are presented as an average of 
duplicates and results from LC/MS were corrected for extraction efficiency.  The stability 
study of PP in serum, tumor cytosol and tumor tissue homogenate is shown in Fig. III-1.  
The PP is stable in this particular concentration of cell homogenate attaining under 1% 
conversion to PTX after 36 h.  The PP is similarly stable in serum attaining about 1.5% 
conversion to PTX within 72 h.  Under the experimental conditions, the PP was also stable 
in the tumor tissue homogenate only attaining 5.5% conversion to PTX after 72 h.   
4.5. Pharmacokinetics/Biodistribution   
The PP formulation shows a rapid distribution (Fig. III-2) from the vasculature over 6 
h accounting for a 10-fold dilution of concentration as is common for albumin based  
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Table III-2.  Total Growth Inhibition of PP and PTX from the NCI-60 DTP Human Tumor Cell 
Line Screen.  For simplicity, only the TGI data is presented for 2 cell lines representative of 
each type of cancer.  The cell lines were selected  as having the highest toxicity for PTX and 
PP.  The results show PTX is consistently more cytotoxic than PP most likely due to the 
slow conversion of PP to PTX. 
 
 
 
  
Figure III-1. Biochemical stability of PP in various biological milieus.
PP and PTX were quantified by LC/MS over 36 or 72 h in duplicate in undiluted murine 
serum, CT26 murine tumor cell homogenate and CT26 tumor 
formulation appears to be highly stable to all three matrices sh
to free PTX over the course of 72 h.  
quantitated by LC/MS; extraction from the various tissues was shown to be 
90% for all matrices.  Error bars represent the s
duplicate. 
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The data is presented as a fraction of the total amount 
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Figure III-2. Serum pharmacokinetics for [3H]-PP-HSA and [3H]-TAXOL in CT26 tumor 
bearing mice. as determined by liquid scintillation counting of serum samples in triplicate.  
The insert magnifies the terminal phase of each treatment which was used to calculate the 
half-life, t1/2 in Table III-2, and shows the disparity of clearance rates between the two 
formulations.  The reason for the rebound in PP concentration at 6 h is unknown but may be 
due to enterohepatic recycling.  Error bars represent the standard deviation calculated from 
n = 3 mice in triplicate. 
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therapies33.  The concentration then rebounds to about 20% of the initial concentration with 
a secondary peak that is within the quantified error.  This concentration is then cleared very 
slowly with a half-life of 23 h.  Biodistribution analysis shows accumulation primarily in the 
liver and spleen (Fig. III-3).  The concentration in these organs is slowly diminished with 
quantifiable concentrations remaining at 72 h.  The tumor rapidly accumulates 1-3% of the 
dose/g tissue which remains constant through 72 h.  The rebound in concentration observed 
in the serum is mirrored in the various organ tissues.  Paclitaxel from the TAXOL formulation 
shows a similarly rapid distribution (Fig. III-2).  There is no rebound and the estimated 
terminal half-life of the formulation is 7 h.  Biodistribution analysis shows accumulation 
primarily in the liver and kidneys (Fig. III-4), which eliminate PTX quickly from the system.  
The tumor shows a comparable uptake of about 3% of the dose/g tissue however 
concentrations approach the lower limit of detection by 6 h.  
The serum pharmacokinetics were analyzed using non-compartmental analysis. The 
major pharmacokinetic parameters were extracted and presented in Table III-3.  The PP 
formulation shows a 3.5-fold increased serum half-life due to a lower systemic clearance 
and volume of distribution.  Consequently, while at only half the dose of TAXOL, PP shows 
a higher C0, area under the curve (AUC) and mean residence time (MRT) in the system.   
4.6. Pharmacodynamics   
The albumin bound form of PP is expected to be significantly better tolerated than 
TAXOL due to the lack of required solvents and surfactants for dissolution as well as the 
slow release profile from the protein.  This is in similar fashion to ABRAXANE.  Due to the 
slowed clearance of PP compared to TAXOL, the bound PTX should have greater exposure 
to the tumor site albeit with only very moderate uptake.  No mice died during the experiment 
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Figure III-3. Time resolved biodistribution of [3H]-PP-HSA in CT26 tumor bearing mice.  The 
liver and spleen are the major sinks for PP, however, the concentrations of PP in the 
respective tissues do not quickly drop but appear to mirror the serum concentrations.  This 
could suggest the PP is intact in the various organs and is leeching back into the 
vasculature over time thus giving rise to the 23 h terminal half-life of the formulation.  Error 
bars represent the standard deviation for n= 3 mice measured in duplicate. 
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Figure III-4. Time resolved biodistribution of [3H]-TAXOL in CT26 tumor bearing mice.  The 
liver is the major uptake organ for TAXOL and the concentrations of PTX in the organ 
disappear very rapidly, mirroring the serum concentrations.  This is clearance of PTX from 
the system and is the primary reason the TAXOL formulation has a short 7 h terminal half-
life.  Error bars represent the standard deviation for n = 3 mice in duplicate. 
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Table III-3. Summary of important pharmacokinetic parameters for [3H]-PP-HSA and [3H]-
TAXOL. The PP formulation shows a much greater retention in the vasculature, most likely 
due to tight albumin binding, which is manifest in a 23 h half-life.  This also results in slower 
clearance from the system and consequently higher exposure to the tumor tissue even 
though the dose of PP is almost half the dose of TAXOL.  A non-compartmental model was 
fitted to both formulations with a weighting of 1/Y using Winnonlin (Pharsight).  C0, estimated 
initial serum concentration; Vd, volume of distribution; Cl, systemic clearance; AUC, area 
under the curve; MRT, mean residence time.  
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but all were sacrificed when the tumor burden exceeded allowable limits; this precluded 
continuation of the study after 9 days for most of the mice.  Within this timeframe at a lower 
dose of 7 mg/kg with respect to PTX in the PP formulation compared to 10 mg/kg formulated 
as TAXOL, there was no statistical difference between any treatment group as analyzed by 
one-way ANOVA (Fig. III-5).  
5. Discussion 
The purpose of synthesizing the PP conjugate was to improve the solubility and 
pharmacokinetics of PTX by mimicking the endogenous serum protein, albumin.  Loading of 
albumin with PP was exceedingly slow taking 2 weeks to reach only 54 µg/mL with respect 
to PTX.  This is in contrast to the expected 3 mg/mL at saturation of 6 binding sites of 4% 
HSA. The slow binding could be a result of rate-limiting dissolution. To facilitate the kinetics 
of binding, PP was dissolved in t-BuOH prior to mixing with a solution of 4% HSA in water.  
Much of the PP precipitates but this process can result in much higher concentrations of PP; 
adding 12 eq of PP allowed full saturation of 6 binding sites of HSA.   
The PP is stabilized in the form of 120 nm particles which remain after lyophilization 
and reconstitution in isotonic solutions.  The structural details of the particles is not known, 
however it is hypothesized the paclitaxel moiety of the PP on the surface of albumin can 
interact with other paclitaxel moieties via van der Waals interactions or bind other molecules 
of albumin through  PTX specific binding sites34.  Formulation of PTX without the PDG 
moiety in this manner saturates at 0.5 eq PTX/HSA with formation of 120 nm particles as 
confirmed by DLS.  This finding suggests particle formation is a PTX-specific phenomenon.  
This finding is similar to ABRAXANE but with notably lower saturable concentrations. 
ABRAXANE allows solubilization of 10 equivalents of PTX/HSA compared to a maximum of 
0.5 by simple mixing. 
 
  
 
 
 
Figure III-5.  Efficacy of PP-
measured with vernier calipers every 3 days with injections on day 0, 3 and 6.  Mice were 
sacrificed when the tumor burden exceeded allowable limits forcing the study to conclude 
after 9 days.  By one-way ANOVA, no statistical significance ex
treatments within this timeframe.  Error bars represent the standard deviation of a population 
of n = 6 mice.   
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The PP conjugate is less cytotoxic than PTX towards a variety of human cancer cell 
lines when tested in vitro (Table III-2).  The mechanism of action of PTX is to bind and 
prevent microtubulin assembly, however various derivatives of paclitaxel have been shown 
to relinquish this binding capacity yet retain varying degrees of cytotoxicity20,35.  This 
appears to be regiospecific as succinate esters on the 2’-OH or 7-OH also abolish 
microtubule binding29 whereas the 1-OH succinate ester retains it36.  Most likely the PP 
conjugate is also unable to bind microtubules explaining the decreased cytotoxicity.  The PP 
conjugate was shown to be highly stable in a variety of milieu including undiluted murine 
serum, CT26 cellular cytosol and CT26 tissue homogenate over 72 h.  The short time scale 
of 4 h for the in vitro cytotoxicity assay suggests the active PTX will not form which could 
explain why the PP conjugate itself is less toxic. 
Ideally albumin-bound drugs will remain invisible to the liver, reticuloendothelial 
system (RES) as well as various esterases and peptidases encountered in the body.  The 
release mechanism for bound drugs would then be concentration-driven dissociation or 
release due to digestion of the carrier albumin.  A dialysis experiment aimed at assessing 
the off-rate of PP from albumin shows this too is very slow, even when sink conditions are 
created by dialyzing against similar concentrations of delipidated albumin.  Thus, 
spontaneous dissociation from the intact protein may not be the major release mechanism 
for PP in vivo.  Since the PP conjugate is utilizing albumin’s natural utility as a fatty acid 
carrier but is not subject to rapid dissociation, albumin is expected to impart its physiological 
profile to the conjugate.   Upon bolus intravenous injection, a 10-fold dilution of the complex 
should ensue33.  This is not irreversible clearance from the body as the re-equilibration of the 
albumin back into the vasculature via the thoracic duct gives rise to the protracted half-life 
observed.  After equilibration, the concentrations in the organs decreased slowly as the bulk 
of the complex was returning to the vasculature as opposed to being systemically cleared.  
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This observed serum half-life of 23 h is in agreement with another report on human serum 
albumin in mice.  The truncated half-life is derived from human serum albumin lacking the 
ability to bind murine FcRn37, the protein responsible for the protracted half-life. 
The biodistribution analysis (Fig. III-3) suggests the majority of the conjugate is in the 
liver and the spleen which could be indicative of sequestration by the RES, however the 
concentrations in the liver and spleen appear to decrease at the same rate as the other 
organs which are not associated with RES.  The higher uptake could then be simply a 
reflection of organ size and vasculature leakiness.  Considering the PP formulation 
generated 120 nm aggregates, the PP-HSA particles could also be sequestered by the 
parenchymal cells of the spleen and liver.   
The volume of distribution, Vd, is a ratio estimating the amount of drug in the tissues 
as compared to the amount of drug in the blood.  Larger volumes of distribution are common 
for lipophilic drugs suggesting they tend to thoroughly permeate through the tissues of the 
body with little remaining in the blood.  Lower volumes of distribution reflect hydrophilic 
drugs that do not readily permeate the endothelium or lipophilic drugs that are highly protein 
bound causing retention in the vasculature.  The apparent Vd for PTX from the TAXOL 
formulation (120 mL) was much higher than from the PP formulation (36 mL) suggesting 
PTX from the former permeates the tissues more readily. While both species are highly 
lipophilic and bind albumin, the substantial decrease in Vd from TAXOL to PP is indicative of 
a stronger binding of PP with albumin than TAXOL.  Thus, PTX is expected to dissociate 
from albumin more readily than PP in various tissues, particularly the liver and kidneys, 
allowing rapid clearance.  The PP formulation shows a twofold higher initial concentration 
and greater AUC compared to the TAXOL formulation despite being half the dose; again 
most likely due to the large Vd for TAXOL. The longer retention within the vascular bed 
means more drug will be exposed to the tumor due to multiple passes through the tumor 
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vasculature with about a 4.5-fold increase in mean residence time (Table III-3).  Because of 
this, PP may be equitoxic to TAXOL at lower doses.  The tumor accumulation of PP is 
minimal, ~1% dose/g tissue.  This is comparable to TAXOL, however the PTX is cleared 
from the tumor within 6 h when formulated as TAXOL.  When formulated as PP, the 
radioactivity from PTX shows a sustained accumulation in the tumor even at 72 h.  The 
comparable tumor uptake suggests PP-HSA may only be taken up passively by tumors.  As 
such, it is unlikely that  murine gp60, as in the case with  murine FcRn,  plays a role in the 
transcytosis of human serum albumin so no active accumulation of albumin is occurring. 
The notable resurgence of PP at about 6 h is within the expected error. Secondary 
peaks in the circulation can occur for a variety of reasons, the most likely being 
enterohepatic recycling38,39.  In this process, the PP is excreted into the biliary canalicula in 
the liver and passed into the jejunal portion of intestine.  The PP can then be reabsorbed 
into the portal blood stream.  This process is slow and can be modeled as if it happens a 
time τ after the bolus injection40.  Unfortunately, the limited amount of data precluded 
successful modeling in this manner so a noncompartmental model was fit to the data as is 
common for this type of profile41,42.  
Submicron particles, including albumin, do not diffuse far into the high-pressure 
tumors43. In order for the PP-HSA complex to be cytotoxic, the albumin must be degraded in 
the tumor environment releasing PP; further hydrolysis to PTX would promote the greatest 
efficacy.  Digestion in the tumor vicinity of albumin is expected to be rapid12.  Conversely, as 
shown in Fig. III-1, the PP conjugate appears to be resistant to hydrolysis in both CT26 
tumor cell cytosol as well as the tumor tissue homogenate.  The decreased cytotoxicity will 
require greater doses of the PP conjugate in the tumor environment.  A greater exposure is 
expected in the tumor environment due to the protracted half-life of the PP-HSA formulation, 
however only moderate tumor uptake is observed.  Despite this, tumor accumulation is 
91 
 
observed for 72 h (Fig. III-3) for the aggregates whereas the PTX is cleared within 6 h for 
the TAXOL vehicle (Fig. III-4).  The utter insolubility of PP mandates formulation in a 
solution containing albumin. This process entails PP precipitation and protein aggregation.  
As such a careful process control must be satisfied in scale-up. Apart from this, the PP-
containing formulation is capable in providing: (1) a solution devoid of any undesirable 
detergents; (2) a cost-effective method for high affinity albumin binding via the simple 
reaction with PDG’s one-step chemistry, (3) similar characteristics as ABRAXANE and (4) 
superior pharmacokinetics. 
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1. Summary                
 The flagship therapeutic molecule selected for PDG modification was PTX.  As a 
result of high affinity for albumin, it was expected the PP conjugate would have increased 
solubility, stability in vivo, a protracted circulation half-life and tumor accretion.  Degradation 
of the albumin in the tumor periphery would release PP for diffusion into the tumor core.    
Experimentally, the PP conjugate was very slowly hydrolyzed in undiluted serum, CT26 
tumor cell cytosol and CT26 tumor tissue homogenate over 72 h at 37°C.  Like all other PTX 
conjugates at the 2’-OH, the cytotoxicity of the conjugate decreased most likely due to loss 
of microtubulin bundling (1-3).  Dialysis of the PP-HSA complex against equimolar 
concentrations of delipidated HSA showed a great deal of stability.  The aggregates should 
be very stable in vivo with little dissociation of PP over time.  Pharmacokinetic and 
biodistribution analysis showed a large increase in circulatory half-life compared to TAXOL 
but only moderate tumor accumulation although uptake is sustained for 72 h.  The fraction of 
dose that does reach the tumor will be inefficiently hydrolyzed to the more active PTX prior 
to clearance from the system.  The result is a formulation comparable to TAXOL at lower 
doses very similar to ABRAXANE.    
The PP conjugate is approximately 10-fold less soluble than PTX.  This was 
marginally improved by the addition of albumin, however, solutions took two weeks to 
equilibrate and approached significantly lower concentrations than expected.  This was 
thought to be dissolution rate limited, but PP became saturated in solution without HSA 
much more quickly than the albumin containing solutions.  The kinetics of albumin loading 
should be second order with respect to the concentration of PP and the concentration of 
HSA.  The slow rate could be due to the very low solubility of PP but this does not explain 
the very low equilibrium concentration of PP.  Albumin is highly resistant to solvents (4).  
Thus to increase the solubility, PP was first dissolved in a water miscible alcohol; t-BuOH or 
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EtOH.  The solution of PP in either alcohol was then introduced to an aqueous solution of 
albumin. The equilibrium concentration of PP obtained by this method was much higher than 
without the alcohol, even after lyophilization and reconstitution.  This also resulted in the 
formation of aggregates.  These aggregates also formed when PTX alone was dissolved in 
EtOH and added to albumin; there were no aggregates when stearic acid or PDG acid were 
dissolved in EtOH and added to albumin.  Consequently PTX must be responsible for 
aggregation. 
Albumin is believed to provide two binding sites for PTX with dissociation constants 
of 10-6 and 10-5 M by docking studies (5).  Experimental values are lower, and showed EtOH 
may be required to create binding sites for PTX (6).  How the PTX interacts with the albumin 
in these aggregates is unknown at this time.  Adding multiple equivalents of PTX in EtOH to 
the albumin yielded a maximum concentration of 0.5 molar equivalents PTX/HSA.  This 
value was surpassed by PP which dissolved six molar equivalents of PP when 12 were 
added.  This suggests the PP conjugate interacting with the protein in a different manner 
than PTX alone.  The fatty acid should be most stable within the binding pocket of the 
albumin with the PTX sitting on the surface.  This can hypothetically allow the PTX to 
interact with other binding sites on albumin or other PTX molecules through van der Waals 
interactions yielding a heterogeneous matrix (Fig. IV-1).  
2. Ancillary Data 
The resulting particles are dependent on the electrolyte composition of the bulk 
solvent when mixing and after reconstitution.  The loading efficiency is poorly reproducible 
and the aggregation exceedingly difficult to prevent without adding a large quantity of 
surfactant.  When the PP was dissolved in a micellar solution of T80 or a Miglyol emulsion, it 
poorly transferred to bovine serum albumin immobilized on agarose as compared to 
dissolution of an alcoholic solution containing PP.  This could be due to the high energy of  
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Figure IV-1.  Hypothetical configuration of PP-HSA aggregates.  The bound PP molecules 
orient the PTX into the bulk solvent causing PTX-HSA interactions as well as PTX-PTX 
interactions. 
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the albumin bound complex as a large portion of the PTX moiety will be exposed to the bulk 
aqueous phase.  This high free energy could be dissipated by binding albumin or another 
PTX moiety to exclude bulk water.  When micellar solutions of T80 containing PP with or 
without HSA were administered to CT26 tumor bearing mice, about 85% of the PP was 
distributed to various tissues within the first few hours (Figs. A-6, A-7).  Subsequent to 
equilibration, the radioactivity was cleared slowly from the serum over 72 h with no rebound 
in concentration as observed for the PP-HSA particles (Fig. A-5).  The very similar profile 
compared to the PP-HSA particles of Chapter III suggests the PP may be able to transfer 
from T80 micelles to albumin and mimic its half-life.  From the immobilized BSA-agarose 
experiment, the T80 micellar solution does allow transfer of PP to albumin readily but less 
efficiently than from EtOH alone (Table A-11).  Whether or not the murine albumin forms 
aggregates in vivo after binding PP is unknown, as is the stability of PP-HSA aggregates in 
vivo.  This has not been shown directly as a monomeric solution of PP with HSA has not 
been found that provides high enough concentrations for PK analysis.   
3. Future Experiments 
The lower side-effects expected from a PP-containing formulation may allow a higher 
maximally tolerated dose compared to TAXOL.  A dose escalation study could be conducted 
to determine a more efficacious dose for PP.  Alternatively, improving the formulation begins 
with improving the PP-HSA interaction. The aforementioned in vitro data has demonstrated 
numerous difficulties for the PP molecule to bind albumin. The poor loading efficiency could 
be due to several issues.  First, the very bulky PTX group in PP could sterically hinder the 
binding pocket such that the whole alkyl tail is not able to bind thus decreasing the affinity 
and minimizing binding.  Secondly, the hypothesized convoluted network of binding through 
fatty acid binding sites, PTX binding sites and van der Waals interactions could effectively 
lead to non-covalent cross-linking thus inducing particle formation.  Minimizing these 
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hydrophobic interactions could prevent the formation of 120 nm aggregates allowing 
elucidation of the benefits, if any, of binding native albumin in vivo.   
To test these two hypotheses, the PP conjugate can be synthetically altered.  It has 
been demonstrated succinylation at the hydroxyl on C-7 lowers the affinity of the molecule 
for albumin (7).  Phosphorylation may also inhibit this interaction while also providing two 
negative charges at physiological pH for improving solubility and bulk water deposition 
around PTX in the binding pocket.  This would also create a resistance to aggregation of 
other PTX molecules due to electrostatic repulsion thus removing the van der Waals 
interaction.  With 2.5 anionic charges at physiological pH, this PP derivative may be able to 
form micelles and should not form aggregates when formulated with albumin.  The 
resistance to proper seating in the binding pocket due to steric hindrance can be addressed 
by reacting a tetraethyleneglycol linker between the PTX and the PP molecule.  This would 
improve solubility slightly but more importantly should decrease the steric hindrance of 
binding potentially caused by PTX.  This would not preclude the binding of PTX to other PTX 
molecules or albumin molecules and thus might not eliminate aggregation.  If both are 
unsuccessful, a combination of both modifications may be successful.  Both syntheses can 
be accomplished (Scheme IV-1) with the more complex 7-phosphate being previously 
published (8). 
Synthesis of the tetraethyleneglycol substituted PP can be synthesized by reacting a 
carbobenzyloxy (Cbz) protected propionyl(tetraethyleneglycol)ethylamine with paclitaxel and 
DCC with DMAP at room temperature (Scheme IV-1).  The Cbz protecting group could then 
be removed by hydrogenolysis and the resulting free amine reacted with PDG anhydride in 
DCM at room temperature.  Synthesis of the phosphorylated derivative is more difficult as 
the 7-position is more sterically hindered than the C-2’ position.  The 2’-OH can be protected 
with a trimethylsilyl ether and the 7-OH reacted with tetrabenzyl pyrophosphate in the  
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Scheme IV-1. Proposed Synthesis of two PDG-PTX derivatives.   Reaction Conditions i: 
TMSCl, imidazole; ii: LDA/THF/-30°C, O(PO(OCH 2Ph)2)2; iii: EtOH/HCl(aq), PDG 
anhydride/DMAP room temperature; iv: EtOH/Pd/C(10%)/H2; v: 
DCC/HOOC(CH2)2(OCH2CH2)4CH2CH2NHCbz/DMAP; vi: PDG anhydride.  TMSCl, 
trimethylsilyl chloride; LDA, lithium diisopropylamide; EtOH, ethanol; DMAP, 4-
dimethylaminopyridine; DCC, dicyclohexylcarbodiimide; Cbz, carbobenzyloxy. 
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presence of freshly prepared lithium diisopropylamide (LDA).  Deprotection of the 
trimethylsilyl ether with EtOH in HCl(aq) and reacting with PDG anhydride in the presence of 
DMAP at room temperature will esterify the PDG lipid moiety at the 2’-OH position.  
Hydrogenolysis to deprotect the dibenzylphosphate yields the desired compound.  If neither 
of these drugs are as cytotoxic as PTX and hydrolytically resistant like PP then neither 
would be useful as a drug.  Instead of disguising PTX as a water soluble drug, an 
intrinsically water soluble drug may offer insight into the formation of aggregates.   
The opposite end of the spectrum is a high solubility drug which should demonstrate 
no albumin binding such as the nucleotide antagonist difluorodeoxycytidine or gemcitabine 
(dFdC).  Modification can occur at the C4-exocyclic amine or the 5’-OH selectively (9, 10) 
yielding a drug species that should be water soluble as micelles, bind albumin and not 
aggregate (Scheme IV-2).  These molecules can be synthesized easily and may be more 
amenable to formulation.  Once synthesized, binding affinity can be analyzed by isothermal 
titration calorimetry.  If the molecules can successfully bind albumin, PK/BD studies can be 
conducted using a radiolabel or by LC/MS.  Favorable pharmacokinetic outcomes would 
lead to cytotoxicity and PD studies. 
 
 
 
  
104 
 
 
 
 
 
Scheme IV-2. Proposed synthesis of two PDG-dFdC derivatives. Reaction conditions i: 
((CH3)3CCO)2O; ii: PDG anhydride/DMAP, TFAA/DCM; iii: PDG anhydride/DMAP  DMAP, 4-
dimethylaminopyridine; TFAA, trifluoroacetic anhydride. 
 
 
 
 
 
  
105 
 
4. References 
1. Deutsch, H. M., Glinski, J. A., Hernandez, M., Haugwitz, R. D., Narayanan, V. L., 
Suffness, M., and Zalkow, L. H. (1989) Synthesis of congeners and prodrugs. 3. Water-
soluble prodrugs of taxol with potent antitumor activity, J. Med. Chem. 32, 788-792. 
 
2. Dosio, F., Reddy, L. H., Ferrero, A., Stella, B., Cattel, L., and Couvreur, P. (2010) Novel 
nanoassemblies composed of squalenoyl-paclitaxel derivatives: synthesis, 
characterization, and biological evaluation, Bioconjug. Chem. 21, 1349-1361. 
 
3. Bradley, M. O., Swindell, C. S., Anthony, F. H., Witman, P. A., Devanesan, P., Webb, N. 
L., Baker, S. D., Wolff, A. C., and Donehower, R. C. (2001) Tumor targeting by 
conjugation of DHA to paclitaxel, J. Cont. Rel. 74, 233-236. 
 
4. Kumar, Y., Muzammil, S., and Tayyab, S. (2005) Influence of fluoro, chloro and alkyl 
alcohols on the folding pathway of human serum albumin, J. Biochem. 138, 335-341. 
 
5. Paal, K., Shkarupin, A., and Beckford, L. (2007) Paclitaxel binding to human serum 
albumin--automated docking studies, Bioorg. Med. Chem. 15, 1323-1329. 
 
6. Bertucci, C., Cimitan, S., Riva, A., and Morazzoni, P. (2006) Binding studies of taxanes 
to human serum albumin by bioaffinity chromatography and circular dichroism, J Pharm. 
Biomed. Anal. 42, 81-87. 
 
7. Battaglia, A., Bertucci, C., Bombardelli, E., Cimitan, S., Guerrini, A., Morazzoni, P., and 
Riva, A. (2003) Synthesis and HSA binding characterisation of the water soluble 7-
succinylpaclitaxel, Eur. J. Med. Chem. 38, 383-389. 
 
8. Vyas, D. M., Wong, H., Crosswell, A. R., Casazza, A. M., Knipe, J. O., Mamber, S. W., 
and Doyle, T. W. (1993) Synthesis and antitumor evaluation of water soluble taxol 
phosphates, Bioorg. Medicinal Chem. Lett. 3, 1357-1360. 
 
9. Bender, D. M., Bao, J., Dantzig, A. H., Diseroad, W. D., Law, K. L., Magnus, N. A., 
Peterson, J. A., Perkins, E. J., Pu, Y. J., Reutzel-Edens, S. M., Remick, D. M., Starling, 
J. J., Stephenson, G. A., Vaid, R. K., Zhang, D., and McCarthy, J. R. (2009) Synthesis, 
Crystallization, and Biological Evaluation of an Orally Active Prodrug of Gemcitabine, J. 
Med. Chem. 52, 6958-6961. 
 
10. Guo Zw, Z., and Gallo, J. M. (1999) Selective Protection of 2',2'-Difluorodeoxycytidine 
(Gemcitabine), J. Org. Chem. 64, 8319-8322. 
 
 
 
  
 
 
 
 
APPENDIX 
 
 
 
ANALYSIS OF PP-HSA AGGREGATES 
 
 
  
107 
 
1. Solubility of PP in the Presence of HSA  
 Stocks of 4%, 3%, 2%, 1% and 0% (w/v) HSA (Sigma A3782) were prepared in PBS.  
A stock (6.97 mg/8.21x105 dpm/mL) of tritiated PP was prepared and concentrated to a 
solid.  The solid was then added to all HSA stock solutions.  The suspensions were sealed 
and shook vigorously in a water bath at 25°C.  The susp ensions were sampled at 1, 2, 3, 7, 
and 14 days followed by centrifugation at 12,000 x g for 5 min, filtration through a 0.1 µm 
inorganic membrane (Whatman Anotop 10, 6809-1012) and 40 µL aliquots of the 
supernatant were diluted in 5 mL Ultima Gold scintillation cocktail and analyzed by LSC 
(Fig. A-1).  The concentrations of albumin were constant as confirmed by a BCA assay at 
each timepoint. (Pierce).  
2. Solubility of PP as a Function of pH  
 Several buffers were prepared spanning pH 3.5-10 according to Gomori G., (1955) 
Methods Enzymology, 1;138-146 as presented in (Table A-1).  The pH 3.5 buffer contained 
0.075 M formic acid/0.07 M sodium formate/0.03 M sodium chloride.  The pH 4.0 buffer 
contained 0.024 M formic acid/0.07 M sodium formate/0.03 M sodium chloride.  The pH 5.0 
buffer contained 0.034 M acetic acid/0.1 M sodium acetate.  The pH 6.0 buffer contained 
0.006 M sodium succinate/0.031 disodium succinate.  The pH 7.0 buffer contained 0.016 M 
potassium dihydrogenphosphate/0.028 M disodium hydogenphosphate.  The pH 8.0 buffer 
contained 0.16 M tris(hydroxyaminomethane) (Tris) and 0.1 M Tris·hydrochloride.  The pH 
8.5 buffer contained 0.20 M Tris and 0.06 M Tris·hydrochloride.  The pH 9.0 buffer contained 
0.045 M sodium bicarbonate/0.019 sodium carbonate.  The pH 10.0 buffer contained 0.02 M 
sodium bicarbonate/0.027 sodium carbonate.  The pH of the buffers was determined using a 
pH meter (Table A-1) (Accumet Basic AB15, Fisher Scientific).  A stock solution of PP was 
prepared in EtOH at 5.55 mg/1.11x106 dpm/mL.  Aliquots of the stock were added to 
eppendorf tubes and the EtOH evaporated with nitrogen; 2 mg for pH 8.0 and above, 1 mg  
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Figure A-1. Time resolved solubility diagram of PP in the presence of HSA in phosphate 
buffer pH 7.4.  The concentration of PP is given with respect to PTX.  The maximum 
concentration of ~54 µg/mL is well below the expected 3 mg/mL for saturation of 6 binding 
sites of 4% HSA.  The 0% HSA formulation represents the rate at which PP can saturate the 
buffer.  This occurs within 24 h. 
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Expected pH Actual pH before adding PP Actual pH after adding PP 
3.5 3.61 3.59 
4.0 4.21 4.18 
5.0 5.35 5.32 
6.0 6.57 6.49 
7.0 7.09 7.17 
8.0 8.08 7.93 
8.5 8.56 8.40 
9.5 9.64 9.47 
10 10.15 9.82 
Table A-1. Summary of buffers used in pH dependent solubility of [3H]-PP.  All buffers were 
prepared according to (Gomori, G. (1955) “Preparation of Buffers for Use in Enzyme 
Studies”. Method Enzymol 1:138-146.  The addition of the acidic PP molecule was not 
enough to substantially change the pH of any stock. 
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for pH 7 and pH 6, 0.1 mg for pH 5.0 and below.  The samples were capped, sealed 
sonicated for 30 minutes and shook at 37°C for 48 h.  Th e samples were removed and 
allowed to cool to 25°C in a water bath then centrif uged at 16.1 x 1000g for 30 minutes.  
Aliquots of the supernatant were filtered through a 0.22 µm PVDF filter and weighed in 100 
µL triplicates, dissolved in 5 mL Ultima Gold scintillation cocktail and analyzed by LSC (Fig. 
A-2).  The remaining samples were resealed, sonicated for 30 minutes and shook at 37°C 
for another 5 days.  The samples were again cooled to 25°C in a water bath and centrifuged 
at 16.1 x 1000g for 30 minutes.  The bottom of the pH 3.5 and pH 10 tubes was scratched 
with a pipet tube to disturb the cakes.  Large flakes were found at pH 10 and small particles 
found in the pH 3.5 tube suggesting the solutions were saturated.  The samples were 
centrifuged again at 16.1 x 1000g for 30 minutes and the supernatants filtered through a 
0.22 µm PVDF filter and 100 µL aliquots weighed in triplicate, dissolved in 5 mL Ultima Gold 
scintillation cocktail and the samples analyzed by LSC (Fig. A-2).   
3. Circular Dichroism of HSA in the Presence of t-BuOH  
  A stock solution of 26 µM of delipidated HSA (Sigma A1887) in 0.1 M phosphate 
buffer was prepared and aliquoted into 5 samples.  To two of the samples was added t-
BuOH to make a 10% (v/v) solution and to two other samples was added enough t-BuOH to 
make a 20% (v/v) solution.  Of the t-BuOH containing solutions, 1 of each concentration was 
lyophilized overnight to a cake and reconstituted in distilled water to regenerate the 26 µM 
solution.  The 5 samples were then analyzed via CD against a blank of phosphate buffer, 
phosphate buffer with 10% (v/v) t-BuOH or phosphate buffer with 20% (v/v) t-BuOH (Fig. A-
3).  The minor differences observed the spectrum were assumed to be due to minor 
concentration differences.  This was confirmed by plotting the absorbance as a function of 
wavelength (Fig. A-4).  Taking a ratio of all mdeg (λ) of the highest (yellow, 26 µM HSA 20% 
t-BuOH) and lowest (navy, 26 µM HSA) datasets revealed a constant.  The same was true  
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Figure A-2. pH dependent solubility of [3H]-PP.  Concentrations at pH 6.5 and below were 
not quantifiable.  TLC on the quantifiable fractions showed only intact conjugate.   
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Figure A-3. Circular Dichroism analysis of HSA in the presence of t-BuOH.  Data was 
collected using an Applied Photophysics Pistar-180 CD/Fluorescence spectrometer. 
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Figure A-4. Absorbance spectrum of HSA in the presence of t-BuOH.  The minor 
differences in absorbance are most likely due to dilution with t-BuOH and imprecise 
quantities of water added during reconstitution after lyophilization. 
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when applied to absorbance (λ).  This suggests the dilution of HSA as a result of the t-BuOH 
is the cause of the change in CD spectrum, not any change in structure.  In other words, 
from the absorbance (λ) spectrum, it is clear the concentrations are different between 26 µM 
HSA and 26 µM HSA containing 20% t-BuOH.  If each absorbance is normalized to the 
same absorbance, the CD spectra would superimpose. 
4. Effect of PTX on Aggregation of HSA  
  A stock solution of tritiated PTX (AK Scientific, Union City, CA 65648, Moravek 
Biochemicals, Brea, CA MT 1646) in t-BuOH was prepared at 6.41 mg/1.64x106 dpm/mL.  
Stocks of HSA were also prepared as 4 samples of 40 mg/mL HSA (Sigma A1887) in D5W.  
To the albumin stocks was added 1, 2, 3 or 6.5 eq PTX/HSA at a concentration of 1:10 (v/v) 
t-BuOH:D5W.  Increasing turbidity was observed for increasing equivalents of PTX.  The 
samples were gently heated and shook for 5 min then shell frozen at -78°C and lyophilized 
overnight.  Samples were reconstituted with distilled water to 40 mg/mL HSA and 
subsequently centrifuged at 16.1 x 1000g for 10 min.  The supernatants were removed and 
analyzed by DLS then aliquots dissolved in 5 mL Ultima Gold scintillation cocktail and 
analyzed by LSC.  The pellets were also dissolved in MeOH and 5 mL Ultima Gold 
scintillation cocktail and analyzed by LSC for mass balance (Table A-2). 
5. Effect of Loading HSA in Water and Stability of Resultant Particles 
 A 50 mg/mL solution of delipidated HSA (Sigma A1887) in water and a stock of PP in 
t-BuOH (24.7 mg/8.04x105 dpm/mL) were prepared.  To the HSA solution was added 2 eq 
PP in t-BuOH to a final volume of 1:10 (v/v) t-BuOH in water.  The suspension was 
lyophilized to a cake and reconstituted in phosphate buffer.  The suspension was filtered 
through a 0.22 µm PVDF filter yielding a colloidal suspension.  Two aliquots were removed, 
weighed and dissolved in 5 mL Ultima Gold scintillation cocktail for LSC analysis confirming  
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eq 
PTX 
Z ± σ nm 
(PDI) 
Intensity nm 
(%) 
Volume 
nm 
(%) 
Number nm 
(%) 
eq 
loaded 
%PTX 
recovered 
1 70 ± 60 
(0.717) 
165 (90%) 
3 (10%) 
25 (.3%) 
3 (99.7%) 
2 (100%) 0.41 / 1 75% 
2 105 ± 75 
(0.525) 
182 (94%) 
3 (6%) 
3 (100%) 3 (100%) 0.41 / 2 76% 
3 80 ± 60 
(0.556) 
150 (93%) 
3 (7%) 
110 
(0.1%) 
3 (99.9%) 
3 (100%) 0.51 / 3 81% 
6.5 100 ± 70 
(0.484) 
160 (80%) 
30 (12%) 
3 (8%) 
25 (0.3%) 
3 (99.7%) 
3 (100%) 0.47 / 
6.5 
67% 
Table A-2. Particle size and solubility of PTX in PTX-HSA aggregates. PTX only weakly 
binds HSA and appears to form aggregates with HSA.  Saturation of the protein with PTX 
appears to occur at a 1:2 molar ratio. 
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1.9 eq PP loaded.  The suspension was added to a cuvette, sealed and analyzed by DLS 
over 48 h (Table A-3).   
 After 48 h the sample was subject to ultracentrifugation at 14 x 1000g through a 100 
kDa MWCO regenerated cellulose membrane (microcon ultracel YM-100, 42412, lot 
R7PN22647) for 40 min yielding the first filtrate.  The cake was resuspended in 0.1 M 
phosphate buffer and ultracentrifuged at 14 x 1000g through a 100 kDa MWCO regenerated 
cellulose membrane for 40 min yielding the second filtrate.  The cake was then resuspended 
in phosphate buffer yielding the retentate. All three samples were monitored by DLS over 
several days to determine the stability of the individual species (Table A-4). 
 From the retentate, 0.6 mL was aliquoted into six samples of 0.1 mL which were then 
diluted fivefold to 1% HSA with 0.1 M phosphate buffer.  To these samples were added 2% 
(w/v) PEG 3350, 2% (w/v) PEG 8000, 20% (v/v) glycerol, L-Arg at a concentration of 0.5 M 
and 0.1% (v/v) Triton X-100.  The remaining sample was saved as an untreated control.  All 
the samples were mixed gently and analyzed by DLS (Table A-5). 
6. Stability of PP-HSA Particles to Various Additives 
 Stock solutions of500 µL containing 10 mg/mL delipidated HSA (Sigma A1887) were 
prepared in water and additives of various concentrations were dissolved to potentially 
preclude aggregation.  To the final samples was added 2 eq PP in t-BuOH at a final volume 
ratio of 1:10 t-BuOH:water.  The samples were then analyzed using DLS (Table A-6).  The 
samples are compared to reference solutions in which 2 eq PP was added to 10 mg/mL 
delipidated HSA (Sigma A1887) in water at 1:10 (v/v) t-BuOH.  Additionally 50 mg/mL 
delipidated HSA (Sigma A1887) in D5W and a fivefold dilution of the previous sample in 
water were prepared with no t-BuOH or PP.  After DLS analysis (Table A-6) all samples 
(excluding the D5W and D1W solutions) were shell frozen at -78°C and lyophilized over 3  
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 0 days 1 day 2 days 
Z±σ (PDI) 120 ± 60 nm (0.246) 120 ± 60 nm (0.250) 120 ± 60 nm (0.259) 
Intensity 150 nm (100%) 160 nm (100%) 160 nm (100%) 
Volume 130 nm (100%) 130 nm (100%) 130 nm (100%) 
Number 85 nm (100%) 70 nm (100%) 75 nm (100%) 
Table A-3. Stability of PP-HSA aggregates by DLS over 48 h.  The PP-HSA aggregates 
appear stable over 48 h at room temperature. 
 
 
  
118 
 
 
 
 
First Filtrate 
 0 days 1 day 2 days 3 days 
Z±σ (PDI) 8 ± 2 nm (0.073) 12 ± 6 nm (0.236) 9 ± 4 nm (0.182) 8 ± 3 nm (0.101) 
Intensity 9 nm (100%) 13 nm (95%) 
4000 nm (4%) 
3 nm (1%) 
9nm (97%) 
4000 nm(3%) 
9 nm (100%) 
Volume 7 nm (100%) 8 nm (71%) 
3 nm (29%) 
7 nm (100%) 7 nm (100%) 
Number 6 nm (100%) 3 nm (100%) 5 nm (100%) 5 nm (100%) 
 
Second Filtrate 
 0 days 1 day 2 days 3 days 
Z±σ (PDI) 13 ± 8 nm (0.450) 9 ± 5 nm (0.311) 12 ± 7 nm (0.417) 150 ± 90 nm (0.318) 
Intensity 9 nm (68%) 
275 nm (32%) 
8 nm (89%) 
175 nm (10%) 
5000 nm(1%) 
9  nm (72%) 
325 nm (28%) 
8 nm (59%) 
450 nm (38%) 
80 nm (3%) 
Volume 7 nm (100%) 6 nm (100%) 7 nm (100%) 7 nm (100%) 
Number 6 nm (100%) 5 nm (100%) 6 nm (100%) 6 nm (100%) 
 
Retentate 
 0 days 1 days 2 days 3 days 
Z±σ (PDI) 100 ± 50 nm (0.292) 100 ± 50 nm (0.281) 100 ± 50 nm 
(0.264) 
100 ± 50 nm 
(0.272) 
Intensity 140 nm (100%) 140 nm (95%) 
10 nm (5%) 
125 nm (100%) 
 
145 nm (100%) 
Volume 110 nm (100%) 100 nm (98%) 
7 nm (2%) 
110 nm (100%) 105 nm (100%) 
Number 65 nm (100%) 5 nm (100%) 80 nm (100%) 60 nm (100%) 
Table A-4. Equilibrium of PP-HSA monomers and aggregates over 48 h after ultrafiltration.  
Neither the monomers nor aggregates appear to re-equilibrate over 72 h.  This may not be a 
concentration driven phenomenon.  The concentrations of the various samples are 
unknown; it is possible very little albumin was ultrafiltered. 
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Phosphate 
Buffer 
2% PEG 
3350 
2% PEG 
8000 
20% 
Glycerol 
0.5 M L-
Arg 
0.1% 
Triton X-
100 
Z±σ 
(PDI) 
80 ± 45 nm 
(0.292) 
95 ± 50 
nm 
(0.297) 
115 ± 60 
nm (0.281) 
80 ± 45 nm 
(0.292) 
30 ± 28 
nm (0.902) 
15 ± 8 nm 
(0.351) 
Intensity 110 nm 
(94%) 
10 nm (6%) 
135 nm 
(100%) 
160 nm 
(100%) 
115 nm 
(94%) 
10 nm (6%) 
275 nm 
(59%) 
15 nm 
(41%) 
12 nm 
(75%) 
100 nm 
(25%) 
Volume 8 nm (98%) 
80 nm (2%) 
95 nm 
(100%) 
140 nm 
(100%) 
9 nm (97%) 
85 nm (3%) 
10 nm 
(99.7%) 
334 nm 
(0.3%) 
8 nm 
(99.9%) 
75 nm 
(0.1%) 
Number 6 nm (100%) 60 nm 
(100%) 
90 nm 
(100%) 
6 nm 
(100%) 
9 nm 
(100%) 
6 nm 
(100%) 
Table A-5. Stability of PP-HSA aggregates to PEG, glycerol, L-Arg and Triton X-100.  L-Arg 
and Triton X-100 appear to facilitate disaggregation of the particles. Dilution of the particles 
without additive also appears to break the particles indicating it could be a concentration 
driven interaction. This is in contrast to data observed after ultrafiltering the particles. 
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Table A-6.  Effect of various additives on aggregate formation.  Most additives have no 
effect until reconstituted in buffer and only CHAPS, PEG 8000, Pluronic L35 and L-Arg 
appear to be effective. OGP = octylglucopyranoside, CHAPS = 3-[(3-
Cholamidopropyl)dimethylammonio]-1- 
propanesulfonate. 
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days then reconstituted in 0.1 M phosphate buffer.  The samples were filtered through a 
0.22 µm PVDF filter and again analyzed via DLS (Table A-6). 
7. Effect of Albumin Batch on Aggregate Formation   
 Stock solutions of 50 mg/mL of two different albumin batches in 0.1 M phosphate 
buffer were prepared; lyophilized powder, fatty acid free, Globulin free, ~99% (agarose gel 
electrophoresis) (Sigma A3782)   and lyophilized powder, essentially fatty acid free ~96% 
(Sigma A1887). Aliquots of 500 µL were ultracentrifuged through a 100 kDa MWCO 
regenerated cellulose membrane (microcon ultracel YM-100, 42412, lot R7PN22647) at 14 x 
1000g for 40 minutes.  The filtrates should have contained monomeric albumin while the 
retentate should contain any aggregates.  The retentates were resuspended in 500 µL 0.1 M 
phosphate buffer and examined using DLS (Table A-7).  The samples were then incubated 
at room temperature for 48 h and DLS was run again on the filtrates (Table A-7). 
Another batch of 50 mg/mL (Sigma A3782) delipidated HSA in distilled water was 
treated with 3 or 6 eq of PP in t-BuOH (26.4 mg/8.48x105 dpm/mL)  at a ratio of 1:10 or 1:5 
(v/v) t-BuOH:water respectively.  Both suspensions were turbid and centrifuged at 16.1 x 
1000g for 10 min and the supernatant filtered through a 0.22 µm PVDF filter for DLS 
analysis then dissolved in 5 mL Ultima Gold scintillation cocktail for LSC analysis (Table A-
7). 
8. Solvent effect on Aggregate Formation  
  Phosphate buffer appears to help reduce particle size, but also leads to turbidity and 
poor retention of the conjugate via LSC.  Thus it is interesting to determine whether PBS or 
D5W would be better suited for reconstitution.  Solutions of 10 mg/mL HSA (Sigma A1887) 
and 5 mM CHAPS in D5W or water were prepared and 2 eq [3H]-PP (24.7 mg/1.08x106 
dpm/mL) was added in t-BuOH at a 1:10 v/v ratio.  All samples were shell frozen at -78°C  
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24 h 
 5% A3782 5% A3782  
(10% t-BuOH) 
5% A3782  
(10% t-BuOH 3EQ) 
5% A3782  
(20% t-BuOH 6EQ) 
Z±σ (PDI) 5±3 nm (0.302) 18 ± 17nm (0.897) 145 ± 50nm (0.125) 335±105nm (0.096) 
Intensity 3 nm (71%)  
900 nm (19%)  
26 nm (10%) 
290 nm (60%)  
4 nm (35%)  
40 nm (5%) 
163.6 (100%) 365.4 (100%) 
Volume 2 nm (100%)  4 nm (100%)  155 nm (100%) 400 nm (100%) 
Number 2 nm (100%) 3.034 (100%) 115 nm (100%) 320 nm (100%) 
48 h 
 A3782 Filtrate (48h) A1887 Filtrate (48h) 
Z±σ (PDI) 125 ± 125 nm (1.000) 80 ± 55 nm (0.477) 
Intensity 950 nm (63%) 
6 nm (33%) 
5000 (4%) 
5 nm (60%) 
790 nm (36%) 
5000 (4%) 
Volume 5 nm (99.9%) 5 nm (100%)     
Number 5 nm (100%) 4 nm (100%) 
LSC 
Sample Mass (g) Volume (µL) Ρ (g/mL) dpm dpm/mL mg/mL 
Stock 6µL (1) 0.0036 4.61 0.781 4064 8.82x105 26.4 
Stock 6µL (2) 0.0045 5.76 0.781 4684 8.13x105 26.4 
3EQ 200µL (1) 0.1956 195.6 1 6809 34811 0.80 
3EQ 200µL (2) 0.1996 199.6 1 7053 35336 0.81 
6EQ 200µL (1) 0.1928 192.8 1 2602 13496 0.31 
6EQ 200µL (2) 0.1974 197.4 1 2729 13825 0.32 
Table A-7. Effect of albumin purification state on formation of PP-HSA aggregates. A3782 
tends to aggregate equally as poorly as A1887 and has poor loadability.  From LSC: 1 eq = 
0.88 mg/mL. 3 eq: 0.91 eq/HSA loaded (33%) 6 eq:0.35 eq/HSA (16% loaded).  This 
suggests the interaction is not due to albumin after purification by a specific method. 
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and lyophilized overnight.  The resultant cakes were resuspended in water, D5W, phosphate 
bufferor PBS and filtered through a 0.22 µm PVDF filter for DLS analysis (Table A-8).  The 
filtrates were also weighed out, dissolved in 5 mL Ultima Gold scintillation cocktail and 
analyzed by LSC (Table A-8). 
9. Effect of Diluents and Reconstitution Solvent on PP Loading and Aggregate 
Formation  
  The best formulation involves injecting PP in t-BuOH into HSA dissolved in water 
followed by lyophilization and reconstitution in D5W.  Instead of CHAPS, biologically 
compatible surfactants were examined including T20, T80 and TPGS.  The concentrations 
used were 3 molar eq, 3 molar eq and the CMC of 0.02 mM respectively.  Samples of 500 
µL 10 mg/mL delipidated HSA (Biocell, Rancho Dominguez, CA 3101-00, Albumin, Human, 
Cohn Fraction V) in water were prepared and the surfactant was added.  To the mixtures 
was added 2 eq [3H]-PP (24.7 mg/1.08x106 dpm/mL) in t-BuOH in a 1:10 v/v ratio.  All 
samples were lyophilized overnight.  The samples were reconstituted with 500 µL of either 
D5W or PBS.  The samples were filtered through a 0.22 µm PVDF filter and analyzed via 
DLS then dissolved in 5 mL Ultima Gold scintillation cocktail and analyzed by LSC (Table A-
9).   
10. Effect of Fatty Acids on HSA Aggregate Formation   
Stock solutions of 10 mg/mL HSA (Biocell, Rancho Dominguez, CA 3101-00, Sigma 
A3782) were prepared in water.  To the HSA solutions was added 2 eq of stearic acid or 
PDG acid both ~1 mg/mL in t-BuOH at a ratio of 1:10 (v/v) t-BuOH:water.  The samples 
were compared to 10 mg/mL standards of both albumin stocks in water and in 10% t-BuOH 
in water.  No turbidity was observed in any sample, nor did any sample appear colloidal 
which was confirmed by DLS (Table A-10).  All samples were shell frozen at -78°C and  
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 D5W/water Water/D5W Water/0.1M PB Water/PBS 
Z±σ (PDI) 115 ± 60 nm 
(0.264) 
20 ± 15 nm 
(0.554) 
150 ± 70 nm 
(0.200) 
150 ± 150 nm 
(1.000) 
Intensity 150 nm (100%) 115 nm (52%) 
10 nm (48%) 
190 nm (100%) 1700 nm (73%) 
9 nm (14%) 
70 nm (13%) 
Volume 125 nm (100%) 7 nm (100%) 180 nm (100%) 1900 nm (1%) 
6.5 nm (99%) 
Number 80 nm (100%) 5.5 nm (100%) 100 nm (100%) 5.5 nm (100%) 
# EQ / 
HSA 
0.68 1.1 0.08 0.35 
Table A-8. Effect of diluent and reconstitution solvent on aggregate formation. Ionic systems 
are unfavorable for HSA loading and water is more favorable for loading than D5W.  The 
effect on the secondary structures of albumin after dissolution in water was not examined.  
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 T20 PBS T20 D5W T80 PBS T80 D5W TPGS PBS TPGS 
D5W 
Z±σ 
(PDI) 
85±75 nm 
(0.753) 
110±81 nm 
(0.520) 
125±93 nm 
(0.552) 
130±78 nm 
(0.349) 
115±60 nm 
(0.261) 
100±50 nm 
(0.251) 
Intensity 225 nm 
(87%) 
8nm (13%) 
180 nm 
(93%) 
9 nm (7%) 
240 nm 
(92%) 
9 nm (8%) 
200 nm 
(94%) 
9 nm (6%) 
155 nm 
(100%) 
125 nm 
(100%) 
Volume 230 nm 
(0.2%) 
7 nm 
(99.8%) 
170 nm 
(1%) 
8 nm 
(99%) 
8 nm 
(99.3%) 
90 nm 
(0.3%) 
315 nm 
(0.4%) 
8 nm  
(99%) 
105 nm 
(0.5%) 
275 nm 
(0.5%) 
120 nm 
(100%) 
100 nm 
(100%) 
Number 6 nm 
(100%) 
7nm 
(100%) 
7 nm 
(100%) 
7 nm 
(100%) 
65 nm 
(100%) 
65 nm 
(100%) 
EQ / 
HSA 
0.31 0.52 0.88 1.03 1.05 1.41 
Table A-9.  Effect of T20, T80 and TPGS surfactants on PP-HSA aggregate formation.  Both 
Tweens appear to minimize aggregate formation but T80 offers a higher loading capability.  
Only 50% of the added 2 eq bound HSA. 
 
 
  
126 
 
 
 
 
 
 Z (PDI) Intensity Volume Number 
A3782 (Aq) 130±125 nm 
(0.897) 
1000 nm (42%) 
115 nm (31%) 
3 nm (14.6%) 
2 nm (99.9%) 
15 nm (0.1%) 
2 nm (100%) 
A3782 10% t-
BuOH 
125±125 nm 
(1.000) 
950 nm (63%)               
6 nm (33%)                  
5000 nm (4%) 
5 nm (99.9%)                   
1100 nm (0.1%) 
5 nm (100%) 
A3782 10% t-
BuOH 2EQSA 
70±70nm 
(1.000) 
320 nm (84%) 
4 nm (15%) 
5000 nm (1%) 
3 nm (100%) 3 nm (100%) 
A3782 10% t-
BuOH 
2EQPDG 
100±100nm 
(1.000) 
265 nm (81%) 
4 nm (15%) 
5000 nm (4%) 
4 nm (100%) 3 nm (100%) 
Biocell (Aq) 15±10nm  
(0.445) 
9 nm (60%) 
70 nm (30%) 
3500 nm (10%) 
7 nm (99.9%) 
50 nm (0.1%) 
5 nm (100%) 
Biocell 10% t-
BuOH 
14±8nm  
(0.364) 
12 nm (74%) 
115 nm (26%) 
8 nm (99.9%) 
85 nm (0.1%) 
7 nm (100%) 
Biocell 10% t-
BuOH 2EQSA 
55±50nm 
(0.792) 
550 nm (50%) 
10 nm (30%) 
50 nm (13%) 
8 nm (99%) 
40 nm (1%) 
7 nm (100%) 
Biocell 10% t-
BuOH 
2EQPDG 
110±80nm 
(0.499) 
440 nm (49%) 
10 nm (37%) 
40 nm (11%) 
500 nm (0.1%) 
9 nm (99.3%) 
35 nm (0.5%) 
8 nm (100%) 
 A3782 PDG A3782 SA Biocell PDG Biocell SA 
Z (PDI) 12±7nm  
(0.389) 
11±7nm (0.368) 17±13nm 
(0.579) 
27±21nm 
(0.628) 
Intensity 9 nm (70%) 
115 nm (30%) 
9 nm (74%) 
140 nm (26%) 
120 nm (51%) 
9 nm (49%) 
105 nm (66%) 
9 nm (33%) 
4500 nm (1%) 
Volume 7 nm (100%) 7 nm (100%) 7 nm (99.9%) 
75 nm (0.1%) 
8 nm (99.7%) 
75 nm (0.3%) 
Number 6 nm (100%) 6 nm (100%) 6 nm (100%) 7 nm (100%) 
Table A-10.  Formation of HSA aggregates using stearic or PDG acid.  Both stearic and 
PDG-acid appear to completely solubilize in the presence of albumin but do not form 
aggregates at 2 eq/HSA.  Addition of the lipids without HSA causes turbidity.  This suggests 
the PP-HSA aggregation is a PTX specific phenomenon. 
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lyophilized overnight. The cakes were reconstituted in 0.1 M phosphate buffer and analyzed 
by DLS again (Table A-10). 
11. Formulation of PP as a Tween 80/Miglyol Emulsion   
 A 5% (o/w) emulsion was desired so the amount of surfactant to stabilize the 
emulsion was estimated accordingly.   
T80 FW = 1310 g/mol       Miglyol 812 ρ = 0.95 g/mL 
Assume: 200 nm particles (r = 100 nm), 5% oil/water emulsion, T80 molecular surface area 
= 50 Å2/molecule T80 
Total volume: 
5 g Miglyol / 100 g emulsion 
5 g Miglyol * 0.95 g/mL = 4.75 mL Miglyol (Total Volume of Miglyol) 
Drop volume: 
100 nm = 0.1 µm = 0.0001 mm = 0.00001 cm 
V = 4/3πr3 = 4/3 * 3.14 * (0.00001cm)3 = 4.19 x 10-15 mL / drop Miglyol 
Drop surface area: 
100 nm = 1000 Å 
SA = 4πr2 = 4 * 3.14 * (1000 Å)2 = 1.26 x 107 Å2 / drop Miglyol 
T80/drop Miglyol: 
(1.26 x 107 Å2 / drop Miglyol) / (50 Å2/molecule T80) = 2.52 x 105 molecules T80 / drop 
Miglyol 
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Drops Miglyol: 
Total volume / drop volume = 4.75 mL Miglyol / 4.19 x 10-15 mL Miglyol / drop = 1.13 x 1015 
drops Miglyol 
Total T80: 
2.52 x 105 molecules T80 / drop Miglyol * 1.13 x 1015 drops Miglyol = 2.85 x 1020 molecules 
T80 
2.85 x 1020 molecules T80 / 6.022 x 1023 molecules T80 / mol T80 = 4.73 x 10-4 mol T80 
473 µmol T80 * 1.31 mg T80 / µmol T80 = 620 mg T80 
620 mg  T80 / 5 g Miglyol / 94.4 g H2O (0.6 : 5 : 94.4)  
~ 1 g T80 / 5 g Miglyol 812 should be able produce ~200 nm particles. 
Formulation: 
Aqueous: 5% dextrose in water, 1% T80 
Oil: 5% Miglyol 
 Added 5% (w/v) Miglyol 812 to a 1% (v/v) EtOH and 1% (v/v) T80 solution in D5W or 
PBS containing 0.08 mg/8.22x104 dpm/mL [3H]-PP stock.  The sample was vortexed for 5 
minutes then emulsified using a tissue Powergen700 tissue homogenizer (Fisher Scientific) 
on speed 7 for 5 minutes.  
12. Albumin-Agarose Extraction of PP from a Tween 80/Miglyol Emulsion  
 BSA-Agarose from Sigma Aldrich (10.1 mg/mL, A3790) was aliquoted as 0.5 mL 
samples which were centrifuged at 3,000 x g for 3 min and the supernatant discarded.  The 
samples were washed twice with D5W, PBS, 1% (v/v) T80 in D5W, 1% (v/v) T80 in PBS, 1% 
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(v/v) EtOH in D5W or 1% (v/v) EtOH in PBS.  The suspensions were centrifuged at 3,000 x 
g for 3 min and the supernatants discarded.  The BSA-Agarose was then resuspended in 
0.4 mL of the test solution.  To the BSA-Agarose samples was added 40 µL of t-BuOH stock 
(Table A-11) or 0.4 mL of the Miglyol emulsion which already contained the radiolabeled 
PP.  The samples were rocked at room temperature for 1 h.  The samples were then 
centrifuged at 3,000 x g for 3 min and an aliquot of the supernatant filtered through a 0.22 
µm polycarbonate membrane, (Poretics, Cat: 11013, Material: 1220693, Batch: 215896) 
dissolved in 5 mL Ultima Gold scintillation cocktail and analyzed by LSC to determine the 
percent of the dose that precipitated (Table A-11).  The remaining supernatant, along with 2 
washes of the resin with D5W or PBS, were dissolved in 5 mL Ultima Gold scintillation 
cocktail and analyzed by LSC to determine the filtrate concentration (Table A-11).    
13. Formulation of PP as Pluronic F-68/Miglyol Emulsion   
 The Miglyol 812 samples were prepared by adding 40 µL of PP stock (0.334 mg/ 
6.18x106 dpm/mL) to 50 µL of Miglyol 812.  The EtOH was removed via a stream of 
nitrogen.  To this was added 200 µL of 2% (w/v) Pluronic F-68 (poloxamer 188) in D5W.  
The two layers were vortexed heavily for 20 minutes then passed through a 0.22 µm 
polycarbonate membrane. (Poretics, Cat: 11013, Material: 1220693, Batch: 215896) This 
was done using an extruder under pressure with nitrogen for 5 extrusions.  The amount of 
material yielded was little ~60 µL.  Because of this, 25 µL of the emulsion was used in 
duplicate. 
14. Albumin-Agarose Extraction of PP from a Pluronic F-68/Miglyol Emulsion  
  BSA-agarose (10.1 mg/mL, Sigma A3790) was aliquoted as 1 mL fractions into 4 
different 1.5 mL eppendorf tubes.  The tubes were centrifuged at 3,000 x g for 3 min to pellet 
the agarose and the supernatant decanted.  Two samples were washed twice with D5W 
alone.  Washing involved mixing the thoroughly suspending the resin in solvent then  
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t-BuOH stock 0.8 
mg/mL 
 
mass volume dpm dpm/mL 
0.0191 0.024455826 20167 824630 
0.0199 0.025480154 21066 826761 
0.0199 0.025480154 21027 825231 
0.0384 0.049167734 40480 823304 
0.0396 0.050704225 41227 813088 
0.038 0.04865557 39882 819680 
AVERAGE   822116 
 
D5W super 
dpm 
filtrate dpm % 
bound 
% 
supernatant 
% 
precipitated 
Miglyol 14235 5701 31 69 15 
      
w/ T80 13119 6954 37 63 7 
      
w/o T80 3994 187 81 19 11 
 
     
PBS super 
dpm 
filtrate dpm % 
bound 
% 
supernatant 
% 
precipitated 
Miglyol 9375 4071 55 45 9 
      
w/ T80 5717 2524 72 28 4 
      
w/o T80 3453 795 83 17 6 
Table A-11. Transfer of PP from t-BuOH, a Miglyol 812 emulsion or T80 micelles to BSA 
immobilized on agarose.  All dpms unaccounted for were assumed to be bound.   All values 
reported are % added dose.  PBS appears more conducive to PP transfer than D5W. 
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centrifuging at 3,000 x g for 3 min and decanting the supernatant.  To these solutions was 
then added 300 µL D5W and the suspension was warmed to 37°C in the incubator.  The 
remaining two samples were were washed thrice via the same procedure but with 5 mM 
CHAPS (~3 mg/mL) in D5W.  To these agarose pellets were added 400 µL D5W/5 mM 
CHAPS and the suspensions warmed to 37°C in the incubato r.  To the 1 mL samples of 
BSA-agarose was added 100 µL (0.0334 mg/6.18x105 dpm/mL) of the [3H]-PP stock or 25 
µL Miglyol emulsion.  The samples were heated to 37°C  and shook for 2 h. 
 Standards were run for each formulation (assumed ρ = 1.02 g/mL for Miglyol 
formulation, ρ = 0.789 for EtOH).  For the various formulations, aliquots of the stock solution 
were weighed out, dissolved in 5 mL Ultima Gold scintillation cocktail and analyzed for LSC 
(Table A-12).  The samples were analyzed by centrifuging the agarose at 3,000 x g for 3 
mins then removing the supernatant and adding it to a scintillation vial.  The agarose was 
then washed twice with 400 µL D5W, mixed thoroughly and centrifuged again.  All washes 
were pooled with the initial supernatant.  The pellets were then diluted with 100 µL 1N HCl 
and 400 µL MeCN, vortexed heavily and centrifuged at 3,000 x g for 3 min.  The supernatant 
(bound fraction) was removed and added to a scintillation vial.  The resin was washed with 2 
x 400 µL MeCN, vortexed, centrifuged and the supernatant removed and pooled in the 
bound fraction.  Finally the whole resin was washed into a scintillation vial with acetone 
(resin fraction).  To all samples was added 10 mL Ultima Gold XR scintillation cocktail and 
the samples analyzed via LSC (Table A-12). 
15. TAXOTERE-like Formulation of PP   
 Prepared a solution of 50 mg/mL delipidated HSA (Sigma A1887) in D5W and a 
stock of [3H]-PP (18.73 mg/1.58x106 dpm/mL) in EtOH.  An aliquot of 40 µL of the stock was 
evaporated and resuspended in 8 µL of 1:1 (v/v) T80:EtOH to which was added 400 µL of  
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Miglyol/Pluronic emulsion     
mass (g) volume (mL) dpm dpm/mL   25uL 
samples 
0.0052 0.0051 4056 795600 outlier not averaged 
0.0044 0.0043 13024 3019200    
0.0085 0.0083 27899 3347880   dpm added 
AVERAGE 
  3183540   79589 
 
      
PP stock in EtOH 
    10uL 
samples 
mass (g) volume (mL) dpm dpm/mL    
0.009 0.011406844 22030 1931297 outlier not averaged 
0.0038 0.004816223 87042 18072668    
0.0041 0.005196451 92989 17894712   dpm added 
AVERAGE 
  17983690   179837 
 
      
Miglyol 1 
      
super 
dpm 
bound dpm resin 
dpm 
% super %bound %resin %recovered 
8472 10445 3159 38 47 14 28 
 
      
Miglyol 2 
      
super 
dpm 
bound dpm resin 
dpm 
% super %bound %resin %recovered 
9491 6310 1614 55 36 9 22 
 
      
CHAPS 1 
      
super 
dpm 
bound dpm resin 
dpm 
% super %bound %resin %recovered 
29090 111281 18147 18 70 11 88 
 
      
CHAPS 2 
      
super 
dpm 
bound dpm resin 
dpm 
% super %bound %resin %recovered 
30156 103271 22798 19 66 15 87 
Table A-12. Transfer of PP from a Miglyol emulsion and CHAPS solution to BSA 
immobilized on agarose.  Miglyol 812 again appears to poorly transfer PP to BSA.  The very 
poor recovery of PP from the emulsion could be due to overestimating the specific activity of 
the emulsion due to only a modicum being available for stock characterization. 
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the HSA stock making a final concentration of 1% (v/v) EtOH, 1% (v/v) T80 containing 2 eq 
PP/HSA.  No turbidity was observed in the solution.  The solution was filtered through a 0.22 
µm PVDF filter and the filtrate analyzed by DLS (Table A-13).  Aliquots of the filtrate were 
weighed out, dissolved in 5 mL Ultima Gold scintillation cocktail and analyzed by LSC as 
well (Table A-13). 
16. Analysis of TAXOTERE-like Formulations for Pharmacokinetics   
 To prepare the stock solutions for pharmacokinetic analysis, 6 mg [3H]-PP was 
weighed out and dissolved in a weighed aliquot of 58.5 µL 1:1 (v/v) EtOH:T80 yielding a 
concentration of 97.5 mg/mL.  Half of this stock (30 µL) was diluted to 3 mL with D5W and 
the remaining 30 µL was diluted with 3 mL 50 mg/mL delipidated HSA (Sigma A1887) in 
D5W.  The individual stocks were mixed gently at room temperature, filtered through a 0.22 
µm PVDF filter and the formulation without HSA was diluted 40x from 50 µL (0.0534 g) to 2 
mL (actual dilution 38.2 x) in EtOH using a volumetric flask.  The diluted formulation was 
analyzed by UV to quantify PP (ε228=30,593 M-1cm-1, EtOH).  Aliquots of 250, 100, 50 and 20 
µL of the diluted formulation were then weighed out in triplicate, dissolved in 5 mL Ultima 
Gold XR scintillation cocktail and analyzed by LSC (Table A-14).  Additionally, both 
undiluted stocks were weighed out in aliquots of 20, 50 and 100 µL triplicates, dissolved in 5 
mL Ultima Gold XR scintillation cocktail and analyzed by LSC (Table A-14).   
17. Pharmacokinetics/Biodistribution of TAXOTERE-like Formulations   
 Female 6-8 week old BALB/c mice were inoculated with 5x105 CT26 murine colon 
carcinoma cells on the right flank.  The tumors were allowed to grow for 14 days and the 
mice were randomly sorted into 14 sets of triplicates.  The average tumor size for both 
groups (7 triplicates) was 12.7x8.5 mm for the HSA containing formulation and 12.4x8.3 mm 
for the non HSA formulation (Table A-15).  The mice were injected with 0.104 mg/9.40x106 
dpm/0.1 mL for the HSA containing formulation and 0.105 mg/9.47x106 dpm/0.1 mL for the  
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 Z±σ (PDI) Intensity Volume Number 
TAXOTERE-like 21±20 nm (0.911) 205 nm (56%) 
4 nm (26%) 
30 nm (18%) 
3 nm (99.8%) 
25 nm (0.2%) 
3 nm (100%) 
 
sample mass (g) Volume (µL) dpm dpm/mL mg/mL eq/HSA 
1 0.0262 25.6 3845 150195 1.78 1.93 
2 0.0275 26.8 3917 146157 1.73 1.88 
3 0.0278 27.1 4046 149299 1.77 1.92 
Table A-13.  Particle size analysis of a TAXOTERE-like formulation of PP. The TAXOTERE-
like formulation allows nearly complete solubilization of PP while precluding aggregates from 
forming and only requires 10% of the T80/EtOH used by TAXOTERE. 
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Table A-14.  Characterization of stock solutions of TAXOTERE-like formulations of PP for 
pharmacokinetic analysis.  Since both formulations are derived from the same mother stock, 
the dpm/mg should be constant in both formulations, even if the concentrations are different 
so the HSA containing formulation can be completely quantified from just LSC.  The 
concentrations are nearly identical; 1.04 and 1.05 mg/mL. 
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  With HSA    Without HSA 
 width length volume  width length volume 
 12.34 6.37 970  10.42 8.12 882 
 13.39 6.19 1110  14.04 8.25 1626 
 16.29 12.17 3229  19.24 8.96 3317 
 11.97 8.91 1277  15.47 8.2 1962 
 10.82 8.58 1004  10.87 7.8 922 
 11.55 9.4 1254  13.42 8.01 1443 
 12.53 9.24 1451  12.31 5.93 899 
 10.24 7.61 798  13.47 7.8 1415 
 11.2 8.22 1031  10.36 9.83 1055 
 10.17 9.15 946  12.42 10.67 1646 
 13.42 6.53 1176  11.89 6.07 858 
 14.65 8.1 1738  13.93 6.69 1298 
 19.1 9.33 3404  15.49 12.71 3050 
 10.85 8.87 1044  12.64 10.25 1638 
 9.85 8.41 816  11.99 8.43 1212 
 15.28 5.77 1347  8.43 6.36 452 
 10.94 10.67 1277  10.7 6.99 800 
 10 8.69 869  13.73 10.09 1902 
 14.38 7.72 1596  9.8 9.34 897 
 14.7 7.59 1640  8.3 7.51 517 
 12.26 10.19 1532  11.5 6.6 873 
Average 12.66 8.46 1405  12.40 8.31 1365 
Table A-15.  Tumor sizes of the two treatment groups for the TAXOTERE-like PK study.  
The volume is calculated as (lxw2) where w is the longest diameter. 
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non-HSA containing formulation.  For both experiments, animals were sacrificed at 0.25, 1, 
3, 6, 18, 36 and 72 h.  Prior to sacrifice the mice were anesthetized with 0.1 mL 100 mg/mL 
ketamine hydrochloride intraperitoneally.  Once the mice were unresponsive to toe pinching, 
the mice were exsanguinated by cardiac puncture followed by cervical dislocation.  The 
whole blood was aliquoted as ~200 µL into scintillation vials in triplicate and weighed.  
Target organs were then harvested from the mice, washed thoroughly with PBS, blotted dry 
and small ~100 mg pieces of the organ were weighed in scintillation vials in duplicate.  
 Target organs include the liver, tumor, kidneys, spleen, lungs, heart and injection 
site.  The whole blood was processed by adding 1 mL Solvable® tissue homogenizer (Perkin 
Elmer) and heating to 55°C for 1 h.  The brownish-gr een solution was then treated with 0.1 
mL 0.1 M ethylendiaminetetraacetic acid disodium and 0.3 mL 30% hydrogen peroxide.  
When the foaming settled, the samples were heated to 55°C for an additional hour then 
cooled to ambient and dissolved in 15 mL Ultima Gold XR scintillation cocktail.  The samples 
were equilibrated in the liquid scintillation counter for 1 h prior to counting to adapt to 
temperature and light.  The results of the serum concentrations for both formulations are 
shown in Fig. A-5.  The organs were processed by adding 1 mL Solvable® tissue 
homogenizer (Perkin Elmer) and heating to 55°C for 2 h.  Once dissolved, the yellow 
solutions were treated with 0.3 mL 30% hydrogen peroxide and once the foaming subsided, 
heated to 55°C for an additional hour.  The samples w ere cooled to ambient and dissolved 
in 15 mL Ultima Gold XR scintillation cocktail.  The samples were all mixed thoroughly to 
ensure complete dissolution then the samples were placed in the scintillation counter for 1 h 
prior to counting to adapt to temperature and light.  The uncorrected biodistribution data is 
provided for the HSA containing (Fig. A-6) and non-HSA containing formulations (Fig. A-7).  
The LSC data (Table A-16) was analyzed by noncompartmental analysis using Winnonlin 
(Pharsight) and the major pharmacokinetic parameters extracted (Table A-17).    
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Figure A-5. Serum pharmacokinetics of [3H]-PP in a TAXOTERE-like formulation with or 
without HSA.  Both formulations are nearly superimposable showing the same rapid 
distribution observed with the PP-HSA particles followed by a nearly 24 h terminal half-life.  
Concentrations were calculated by LSC in triplicate without correction by a standard curve.  
Error bars are calculated as the standard deviation from n=3 mice. 
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Figure A-6. Time resolved biodistribution of the [3H]-PP in a TAXOTERE-like formulation 
containing HSA.  Like the PP-HSA particles, there is a rapid accumulation in the liver and 
spleen although clearance from the organs is a slow process.  Tumor accumulation is 
constant but no different from the previous formulation.  Concentrations were quantitated in 
duplicate by LSC without correction by a standard curve.  Error bars are calculated as the 
standard deviation of n=3 mice. 
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Figure A-7.  Time resolved biodistribution of [3H]-PP in a TAXOTERE-like formulation 
without HSA.  Concentrations were quantitated in duplicate by LSC without correction by a 
standard curve.  Error bars are calculated as the standard deviation of n=3 mice.  The BD 
data is also nearly superimposable with the other TAXOTERE-like formulation.   
 
 
 
 
 
 
 
  
141 
 
 
 
 
With HSA 
 
Without HSA 
Table A-16.  Raw data from the TAXOTERE-like PK/BD experiment used in the PK and BD 
analysis.  C, concentration; σ, standard deviation from n=3 mice. 
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Table A-17.  Summary of important pharmacokinetic parameters obtained from 
TAXOTERE-like PP formulations.  A non-compartmental model was fitted to the data with a 
weighting of 1/Y using Winnonlin (Pharsight).  As with the serum pharmacokinetics and 
biodistribution, these results are very similar to the PP-HSA formulation from Chapter III. 
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18. Spectral Data 
 Raw spectral data for all intermediates synthesized in Chapter III are provided 
including mass spectrometry, 1H NMR and 13C NMR. 
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18.1. Ethyl-(E)-octadec-2-enoate (1) 
 
Figure A-8. Mass spectrum of ethyl-(E)-octadec-2-enoate (1). 
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Figure A-9. 1H NMR spectrum of ethyl-(E)-octadec-2-enoate (1). 
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18.2. 3-Pentadecyldiethylglutarate (2) 
 
Figure A-10. Mass spectrum of 3-pentadecyldiethylglutarate (2). 
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Figure A-11. 1H NMR spectrum of 3-pentadecyldiethylglutarate (2). 
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Figure A-12. 13C NMR spectrum of 3-pentadecyldiethylglutarate (2). 
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18.3. 3-Pentadecylglutaric acid (3) 
 
Figure A-13. Mass spectrum of 3-pentadecylglutaric acid (3). 
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Figure A-14. 1H NMR spectrum of 3-pentadecylglutaric acid (3). 
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Figure A-15. 13C NMR spectrum of 3-pentadecylglutaric acid (3). 
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18.4. 3-Pentadecylglutaric anhydride (4) 
 
Figure A-16. Mass spectrum of 3-pentadecylglutaric anhydride (4). 
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Figure A-17. 1H NMR spectrum of 3-pentadecylglutaric anhydride (4). 
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Figure A-18. 13C NMR spectrum of 3-pentadecylglutaric anhydride (4). 
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18.5. Paclitaxel-2’-O-3-pentadecylhemiglutarate (5) 
 
Figure A-19. Mass spectrum of paclitaxel-2’-O-3-pentadecylhemiglutarate (5). 
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Figure A-20. 1H NMR spectrum of paclitaxel-2’-O-3-pentadecylhemiglutarate (5). 
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Figure A-21. 13C NMR spectrum of paclitaxel-2’-O-3-pentadecylhemiglutarate (5). 
